[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 349
1. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • BACKGROUND/AIMS: In view of the increased incidence of carcinoma of the cardia over recent years, this work had the aim of studying the clinicopathological aspects, cell proliferative and tumor apoptotic indices of this neoplasm, their interrelations and possible influences on the prognosis.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • Both age and apoptosis were independent prognostic factors in cancer of the cardia.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


2. Cervantes DT, Fischbach LA: Gastric cardia adenocarcinoma in Taiwanese men: positive associations due to selection bias. World J Gastroenterol; 2010 Mar 28;16(12):1553-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cardia adenocarcinoma in Taiwanese men: positive associations due to selection bias.
  • The factors associated with an increase in gastric cardia adenocarcinoma are poorly understood.
  • In conducting studies to establish the relationship between potential risk factors and gastric cardia adenocarcinoma, it is necessary to carefully consider the role of bias.
  • In a recently published study, the reported associations between H. pylori as well as post-meal physical exertion and gastric cardia adenocarcinoma may have been greatly influenced by selection bias.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori / pathogenicity. Stomach Neoplasms / etiology
  • [MeSH-minor] Asian Continental Ancestry Group. Cardia. Case-Control Studies. Humans. Male. Reproducibility of Results. Risk Assessment. Risk Factors. Selection Bias. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Oct;15(4):697-714 [17030268.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(2):205-14 [17382273.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):351-65 [18318820.001]
  • [Cites] World J Gastroenterol. 2009 Nov 21;15(43):5472-80 [19916179.001]
  • [CommentOn] World J Gastroenterol. 2009 Nov 21;15(43):5472-80 [19916179.001]
  • (PMID = 20333802.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846267
  •  go-up   go-down


3. Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G: Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol; 2010;2010:721485
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma.
  • AIM: Investigate the promoter methylation of the Thrombospondin-1 (TSP1) gene in gastric cardia adenocarcinoma (GCA).
  • [MeSH-major] Adenocarcinoma / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Thrombospondin 1 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2003 Jan 15;116(Pt 2):217-24 [12482908.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):509-19 [11980922.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6299-310 [14559817.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58 [15036264.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):961-8 [15094109.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Jan;68(1):240-3 [5276296.001]
  • [Cites] Blood. 1985 Jan;65(1):79-84 [3965054.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):1059-70 [4030891.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):719-27 [2493001.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):755-61 [2714880.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2899-903 [8428963.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):923-32 [8349738.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] J Cell Sci. 1995 Feb;108 ( Pt 2):797-809 [7539439.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1183-91 [8751720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1793-801 [9528751.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):3534-41 [16951312.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3112-20 [16835379.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5930-9 [17442977.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):14-21 [18425817.001]
  • [Cites] Cell. 2008 Aug 8;134(3):392-404 [18692464.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7090-9 [18757424.001]
  • [Cites] Curr Drug Targets. 2008 Oct;9(10):842-50 [18855618.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):2947-54 [10706681.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):597-614 [11102749.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2427-36 [11160302.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Oncology. 2003;64(4):423-9 [12759541.001]
  • (PMID = 20300551.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thrombospondin 1
  • [Other-IDs] NLM/ PMC2838370
  •  go-up   go-down


Advertisement
4. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Cardia / pathology. DNA Mutational Analysis / methods. Disease Progression. Esophagus / pathology. Female. Humans. Male. Mutation. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


5. Kubo A, Corley DA: Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am J Gastroenterol; 2007 Oct;102(10):2323-30; quiz 2331
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma.
  • OBJECTIVE: The incidence of esophageal adenocarcinoma has been increasing rapidly among many countries.
  • We conducted a systematic review and statistical synthesis of studies that evaluated the associations between vitamin C, vitamin E, or beta-carotene/vitamin A and the risk of esophageal adenocarcinoma or the adjacent gastric cardia (gastroesophageal junction) adenocarcinoma.
  • (b) esophageal or cardia adenocarcinoma occurrence; and (c) a relative risk or odds ratio (OR) with confidence intervals (CI), or sufficient data to permit their calculation.
  • RESULTS: We identified 10 studies (1 cohort, 9 case-control; 1,057 esophageal and 644 cardia cases).
  • Summary estimates stratified by cancer site suggested that higher intakes of vitamin C, beta-carotene/vitamin A, and vitamin E were inversely associated with the risk of esophageal adenocarcinoma (vitamin C, OR 0.49, 95% CI 0.39-0.62, P(heterogeneity)= 0.10; beta-carotene, OR 0.46, 95% CI 0.36-0.59, P(heterogeneity)= 0.82; vitamin E intake, OR 0.80, 95% CI 0.63-1.03, P(heterogeneity)= 0.59).
  • Beta-carotene intake was also inversely associated with the risk of cardia adenocarcinoma (OR 0.57, 95% CI 0.46-0.72, P(heterogeneity)= 0.17).
  • CONCLUSIONS: Pooled results from observational studies suggest that antioxidant intake may be protective against esophageal adenocarcinoma; the data do not support a consistent association between antioxidant intake and the risk of cardia carcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Antioxidants. Cardia. Diet. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581269.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants
  •  go-up   go-down


6. Gao SG, Wang LD, Fan ZM, Li JL, He X, Guo RF, Xie DL, He XW, Gao SS, Guo HQ, Wang JK, Feng XS, Ma BG: Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol; 2005 Aug 14;11(30):4634-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China.
  • AIM: To characterize the histochemical type and pattern of intestinal metaplasia (IM) adjacent to gastric cardia adenocarcinoma (GCA) and distal gastric cancer (GC) in Linzhou, Henan Province, China.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094701.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065871; United States / NCI NIH HHS / CA / CA65871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4615402
  •  go-up   go-down


7. Man XH, Xu Y, Wang ZN, Lü Z, Xu MD, Jiang L, Luo Y, Xu HM, Zhang X: [Loss of heterozygosity at chromosome 8p21-p23 in adenocarcinoma of gastric cardia]. Yi Chuan; 2006 Jun;28(6):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loss of heterozygosity at chromosome 8p21-p23 in adenocarcinoma of gastric cardia].
  • To investigate the involvement of the gene(s) in the carcinogenesis of adenocarcinoma of gastric cardia, loss of heterozygosity (LOH) for microsatellite markers at chromosome 8p21-p23 was examined.
  • Our data indicated that the tumor suppressor gene at chromosome 8p22 might play an important role in the development of adenocarcinoma of gastric cardia.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818423.001).
  • [ISSN] 0253-9772
  • [Journal-full-title] Yi chuan = Hereditas
  • [ISO-abbreviation] Yi Chuan
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


8. Di Martino N, Izzo G, Cosenza A, Cerullo G, Torelli F, Brillantino A, del Genio A: Adenocarcinoma of gastric cardia in the elderly: surgical problems and prognostic factors. World J Gastroenterol; 2005 Sep 7;11(33):5123-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of gastric cardia in the elderly: surgical problems and prognostic factors.
  • AIM: To analyze retrospectively, our results about patients who underwent surgical treatment for adenocarcinoma of the cardia in relation to age, in order to evaluate surgical problems and prognostic factors.
  • METHODS: From January 1987 to March 2003, 140 patients with adenocarcinoma of the cardia underwent resection in the authors institution.
  • CONCLUSION: As the age of the general population increases, more elderly patients with gastric cardia cancer will be candidates for surgical resection.
  • Age alone should not preclude surgical treatment in elderly patients with gastric cardia cancer and a tumor resection can be carried out safely.
  • [MeSH-major] Adenocarcinoma / surgery. Aged. Cardia. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127740.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4320383
  •  go-up   go-down


9. Lagarde SM, Cense HA, Hulscher JB, Tilanus HW, Ten Kate FJ, Obertop H, van Lanschot JJ: Prospective analysis of patients with adenocarcinoma of the gastric cardia and lymph node metastasis in the proximal field of the chest. Br J Surg; 2005 Nov;92(11):1404-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective analysis of patients with adenocarcinoma of the gastric cardia and lymph node metastasis in the proximal field of the chest.
  • BACKGROUND: The extent to which adenocarcinoma of the cardia with lymph node metastasis in the upper mediastinum is amenable to cure by radical surgery is open to debate.
  • METHODS: Some 50 patients with adenocarcinoma of the gastric cardia and substantial invasion of the oesophagus (junctional type II), who underwent an extended transthoracic oesophagectomy as part of a prospective randomized trial between 1994 and 2000, were studied.
  • CONCLUSION: Lymph node metastasis in the proximal field of the chest is common and is an indicator of poor prognosis in patients with adenocarcinoma of the cardia.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Mediastinal Neoplasms / secondary. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127682.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


11. Jovanović I, Todorović V, Milosavljević T, Micev M, Pesko P, Bjelović M, Mouzas Y, Tzardi M: Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum. Vojnosanit Pregl; 2005 Dec;62(12):879-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum.
  • BACKGROUND/AIM: Most studies of esophageal and gastric adenocarcinomas have shown a very high rate of p53 gene mutation and/or protein overexpression, but the influence of the tumour site upon the frequency of p53 protein expression has not been evaluated (gastroesophageal junction, Barret's esophagus, and antrum).
  • METHODS: The material comprised 66 surgical specimens; 10 were Barrett's carcinomas, 25 adenocarcinomas of the gastric cardia (type II adenocarcinoma of the esophagogastric junction - EGJ), and 31 adenocarcinomas of the antrum.
  • There was, however, a significant difference observed in the depth of tumour invasion between Barrett's adenocarcinoma and adenocarcinoma of the cardia compared with the adenocarcinoma of the antrum.
  • Namely, at the time of surgery, both Barrett's adenocarcinomas and adenocarcinomas of the cardia, were significantly more advanced comparing with the adenocarcinomas of the antrum.
  • Overexpression of p53 was found in 40% (4/10) of Barrett's adenocarcinomas, 72% (18/25) of adenocarcinoma of the cardia and 65% (20/31) of adenocarcinoma of the antrum.
  • Patients with more advanced Barrett's adenocarcinoma and in the cases of lymph node invasion revealed tendency for the greater p53 positivity compared with the early forms and lymph node-negative cases; however, this difference was not significant according to the statistical analysis.
  • With regard to adenocarcinoma of the cardia, higher rates of p53 positivity were recorded in poorly differentiated, more advanced cases with lymph node invasion.
  • On the contrary, in the patients with adenocarcinoma of the antrum, greater p53 positivity was revealed in early forms without lymph node involvement, but the observed difference was not statistically significant.
  • CONCLUSION: No significant differences in p53 protein expression in terms of sex, type (Lauren) of tumour, depth of invasion, lymph node involvement, or tumour differentiation were observed in any of the analyzed groups of tumours (Barrett's adenocarcinoma, adenocarcinoma of the cardia and adenocarcinoma of the antrum).
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / complications. Cardia. Esophageal Neoplasms / metabolism. Pyloric Antrum. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Jan;63(1):87-8; author reply 88-9 [16471255.001]
  • (PMID = 16375215.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


12. Bahmanyar S, Ye W: Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer; 2006;54(2):171-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden.
  • In total 185 patients with esophageal adenocarcinoma, 165 with esophageal squamous-cell carcinoma, 258 with gastric cardia adenocarcinoma, and 815 randomly selected population controls underwent face-to-face interviews.
  • A high score of Western diet was associated with increased risks of gastric cardia adenocarcinoma (high 3rd tertile vs. low 1st quartile, OR = 1.8, 95% CI = 1.1-2.9, P for trend = 0.04) and esophageal adenocarcinoma (high 3rd tertile vs. low 1st tertile, OR = 1.6, 95% CI = 0.9-3.1, P for trend = 0.13), whereas a dietary pattern characterized by high beer and liquor intake (alcohol drinker) significantly increased the risk of squamous-cell carcinoma of the esophagus (3rd tertile vs. low 1st tertile, OR = 3.5, 95% CI = 1.9-6.3, P for trend < 0.0001).
  • Our study confirms the important role of diet in the carcinogenesis of esophageal and cardia cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Food Habits. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Aged. Alcohol Drinking. Cardia. Case-Control Studies. Diet Surveys. Factor Analysis, Statistical. Female. Humans. Male. Meat. Odds Ratio. Risk Assessment. Risk Factors. Sweden / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898861.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA57947-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Guimbaud R, Bouché O, Rebischung C, Bonnetain F, Louvet C, Viret F, André T, Samalin E, Gorent J, Dutel J, Bedenne L: Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers.
  • : 4533 Background: There are several standard chemotherapies in locally advanced or metastatic gastric or cardia adenocarcinoma, including ECF.
  • METHODS: Patients (pts) with a gastric or cardiac adenocarcinoma, locally advanced or metastatic, not surgically curable, with a WHO PS ≤2 and evaluable or measurable lesions, were randomized (1:1) according to the following sequences: ECC (epirubicin 50 mg/m<sup>2</sup> D1+ cisplatin 60 mg/m<sup>2</sup> D1 + capecitabine 2000 mg/m<sup>2</sup> D2 to D15, every 3 weeks) in 1st line, then FOLFIRI (IRI 180 mg/m<sup>2</sup> D1, leucovorin 400 mg/m<sup>2</sup> D1, bolus 5FU 400 mg/m<sup>2</sup> D1 and continuous 5FU 2400 mg/m<sup>2</sup> in 46h, every 2 weeks) in 2<sup>nd</sup> line (Arm A) vs the reverse sequence (Arm B) with a stratification for center, PS, adjuvant treatment, site, linitis and measurable disease.
  • Pts characteristics are: PS 1: 51%, med. age 60 years, gastric 67%, M+ 88%, resected primary tumor 27% and linitis 23%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol; 2009 May 20;27(15_suppl):4510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
  • : 4510 Background: Combined pre- and postoperative chemotherapy improves overall survival in operable gastric cancer, although postoperative treatment is not feasible in half of the patients.
  • METHODS: Patients with locally advanced adenocarcinoma of the stomach and cardia were randomized between primary surgery or two 48-day cycles of weekly folinic acid 500 mg/m<sup>2</sup>/2h, 5-FU 2,000 mg/m<sup>2</sup>/24h plus biweekly cisplatin 50 mg/m<sup>2</sup>/1h followed by surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M: Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg; 2006 Oct;30(10):1864-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach.
  • BACKGROUND: Carcinoma arising in the cardioesophageal junction is a distinct clinical entity compared with tumors located in other regions of the stomach.
  • The prognosis for adenocarcinoma of the upper stomach is considered to be relatively poorer than carcinomas of the more distal stomach.
  • We have therefore investigated patients with carcinoma of the gastric cardia in order to evaluate the underlying cause of this poor prognosis.
  • MATERIALS AND METHODS: Clinicopathologic features and postoperative prognosis of 101 patients with carcinoma of the cardia were evaluated and compared with findings on 1884 patients with tumors in other regions of the stomach.
  • RESULTS: Tumors of the cardia had a mean size of 6.8 cm, which was significantly larger than the mean size of 5.9 cm for tumors found in the middle- and lower third of the stomach.
  • The incidence of serosal invasion, lymph node metastasis, and lymphatic and blood vessel invasion was higher in association with adenocarcinoma of the cardia than with adenocarcinoma in remaining parts of the stomach.
  • In the analysis of patients who had undergone curative resection, the 5-year survival rates were 61.6, 79.1, and 82.6% in patients with carcinoma of the cardia, upper one-third, and remaining middle- and lower one-third of the stomach, respectively, and the differences were statistically significant.
  • Multivariate analysis indicated that adenocarcinoma of the gastric cardia is an independent prognostic factor.
  • With regard to the site of recurrence, both lymph node and hematogenous recurrence were observed more frequently in the cardia than in the remaining parts of the stomach.
  • CONCLUSIONS: Our data indicate that the prognosis of patients with adenocarcinoma of the gastric cardia is extremely poor.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Gastric Fundus. Neoplasm Recurrence, Local / epidemiology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] Surg Oncol. 1995;4(2):75-81 [7551262.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):569-74 [1623472.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):514-9 [7960222.001]
  • [Cites] Jpn J Surg. 1989 May;19(3):290-5 [2779027.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Natl Med Assoc. 1995 Jun;87(6):423-6 [7595964.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16983479.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sampliner RE, Camargo E, Prasad AR: Association of ablation of Barrett's esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia. Dis Esophagus; 2006;19(4):277-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ablation of Barrett's esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia.
  • Three cases are reported in which the patient developed adenocarcinoma of the gastric cardia after thermal ablation of HGD.
  • Three cases are reported with long-segment BE and a nodule or mass in the endoscopic cardia post-thermal ablation.
  • Biopsies documented adenocarcinoma of the gastric cardia.
  • The development of adenocarcinoma of the cardia is unexpected.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866860.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Cheng Y, Zhang J, Li Y, Wang Y, Gong J: Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection. BMC Cancer; 2007;7:191
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection.
  • BACKGROUND: The incidence of gastric cardiac adenocarcinoma (GCA) has been increasing in the past two decades in China, but the molecular changes relating to carcinogenesis have not been well characterised.
  • METHODS: In this study, we used a comparative proteomic approach to analyse the malignant and nonmalignant gastric cardia epithelial cells isolated by navigated laser capture microdissection (LCM) from paired surgical specimens of human GCA.
  • [MeSH-major] Adenocarcinoma / metabolism. Cardia / metabolism. Proteome / analysis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2003 May;3(5):610-5 [12748941.001]
  • [Cites] Adv Clin Chem. 2006;42:167-216 [17131627.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):505-9 [12923326.001]
  • [Cites] Duodecim. 1996;112(24):2383-8 [10605239.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5958-65 [10681589.001]
  • [Cites] Electrophoresis. 2000 Jun;21(11):2235-42 [10892734.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Prog Biophys Mol Biol. 2000;73(2-4):91-134 [10958928.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):998-1001 [11020863.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):666-72 [11041055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12601-6 [11050178.001]
  • [Cites] EXS. 2000;(90):462-74 [11268530.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1339-45 [11396210.001]
  • [Cites] Mol Pathol. 2001 Aug;54(4):253-8 [11477141.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):815-22 [11891180.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] Electrophoresis. 2002 Aug;23(15):2513-24 [12210210.001]
  • [Cites] Electrophoresis. 2003 Jan;24(1-2):296-302 [12652601.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3641-4 [14506152.001]
  • [Cites] Cell Cycle. 2003 Nov-Dec;2(6):579-84 [14512773.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):970-9 [14578131.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1988-2001 [14625861.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):335-45 [14973377.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):111-8 [15145526.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5595-605 [15169918.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):363-85 [2017217.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):272-9 [7705958.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Trends Genet. 1998 Jul;14(7):272-6 [9676529.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9018-26 [15604267.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1160-6 [15759317.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):585-91 [15900315.001]
  • [Cites] J Cell Sci. 2005 Jul 15;118(Pt 14):3173-83 [16014382.001]
  • [Cites] Cell Stress Chaperones. 2005 Summer;10(2):86-103 [16038406.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3205-13 [16003825.001]
  • [Cites] Proteomics. 2006 Jan;6(2):538-46 [16342242.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Ai Zheng. 2006 Feb;25(2):194-9 [16480585.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1998-2002 [16287084.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):840-7 [16344274.001]
  • [Cites] Respirology. 2006 May;11(3):269-75 [16635084.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6080-6 [16778180.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1864-9 [16983479.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):131-43 [12871776.001]
  • (PMID = 17927838.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteome
  • [Other-IDs] NLM/ PMC2151079
  •  go-up   go-down


18. van Blankenstein M, Looman CW, Siersema PD, Kuipers EJ, Coebergh JW: Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003. Br J Cancer; 2007 Jun 4;96(11):1767-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003.
  • Over the 15-year period 1989-2003, the incidence of oesophagus-cardia adenocarcinoma in the Netherlands rose annually by 2.6% for males and 1.2% for females.
  • This was the net outcome of annual increases in the incidence of adenocarcinoma of the oesophagus (ACO) of 7.2% for males and 3.5% for females and annual declines in the incidence of adenocarcinoma of the gastric cardia (AGC) of more than 1% for both genders.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Clin Ther. 2001 Dec;23(12):1984-98 [11813933.001]
  • [Cites] Bull World Health Organ. 2002;80(1):26-32 [11884970.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1518-20 [11984536.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Int J Obes Relat Metab Disord. 2002 Sep;26(9):1218-24 [12187399.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] Eur J Clin Pharmacol. 2003 Sep;59(5-6):477-82 [12937872.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2487-94 [14602134.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jan;16(1):69-74 [15095855.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Sep;16(9):903-9 [15316416.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55 [15352913.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):880-7 [15476151.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):826-35 [1186274.001]
  • [Cites] Am J Clin Pathol. 1978 Jul;70(1):1-5 [696666.001]
  • [Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]
  • [Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):130-6 [8691857.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1480-2 [9317067.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):353-60 [10365894.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):391-5 [10405839.001]
  • [Cites] Br J Cancer. 1952 Jun;6(2):127-30 [14954081.001]
  • [Cites] Gut. 2005 Jan;54(1):1-3 [15591495.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):766-74 [15784017.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Gut. 2005 Nov;54(11):1527-35 [16227357.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51 [16282279.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Ned Tijdschr Geneeskd. 2005 Dec 10;149(50):2775-82 [16385829.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • (PMID = 17505507.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359916
  •  go-up   go-down


19. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia]. Chin J Cancer; 2010 Jan;29(1):94-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia].
  • BACKGROUND AND OBJECTIVE: The incidence of adenocarcinoma of the cardia has recently increased.
  • This study compared the clinicopathology and prognosis of patients with gastric cardia adenocarcinoma in different periods between 1984 and 2003.
  • METHODS: A total of 589 patients with pathologically confirmed gastric cardia adenocarcinoma hospitalized in Sun Yat-sen University Cancer Center between 1984 and 2003 were divided into 5-year groups.
  • CONCLUSIONS: During the past 20 years, associated with the upward-trending incidence of gastric cardia adenocarcinoma, the admission rate at our hospital of patients with the tumor increased.
  • [MeSH-major] Adenocarcinoma. Cardia / pathology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038318.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Guo W, Dong ZM, Guo YL, Yang ZB, Kuang G, Shan BE: [Correlation of hypermethylation of TSP1 gene with TGF-beta1 level and T cell immunity in gastric cardia adenocarcinoma]. Ai Zheng; 2009 Dec;28(12):1298-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of hypermethylation of TSP1 gene with TGF-beta1 level and T cell immunity in gastric cardia adenocarcinoma].
  • This study was to investigate the promoter methylation of TSP1 and its correlation with TGF-beta1 level and T cell immunity in gastric cardia adenocarcinoma (GCA).
  • [MeSH-major] Adenocarcinoma. Cardia. Stomach Neoplasms. Thrombospondin 1 / metabolism. Transforming Growth Factor beta1 / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958625.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Thrombospondin 1; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


21. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ: Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep; 2010 Jan;37(1):197-205
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China.
  • The aim of the present study was to investigate the association of single nucleotide polymorphisms (SNPs) in matrix metalloproteinase (MMPs) with the risk of gastric cardia adenocarcinoma (GCA) and esophageal squamous cell carcinoma (ESCC).
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinases / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / epidemiology. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. China / epidemiology. Female. Gene Frequency / genetics. Haplotypes / genetics. Humans. Incidence. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1117-21 [15731163.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7549-58 [11114309.001]
  • [Cites] Matrix Biol. 2002 Oct;21(6):487-98 [12392760.001]
  • [Cites] Circ Res. 2000 May 12;86(9):998-1003 [10807873.001]
  • [Cites] Br Heart J. 1995 Mar;73(3):209-15 [7727178.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] Lung Cancer. 2007 May;56(2):273-80 [17208328.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7622-8 [15492291.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2519-24 [15319302.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2614-20 [17473191.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1834-9 [11701474.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3820-3 [12473595.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1024-9 [16311244.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):197-204 [15609121.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gynecol Obstet Invest. 2008;65(1):68-72 [17851253.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2385-9 [15832405.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):405-9 [15250832.001]
  • [Cites] FEBS Lett. 1996 Feb 12;380(1-2):17-20 [8603731.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1748-53 [15930031.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3987-90 [12873995.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):415-33 [11170864.001]
  • [Cites] Biochem Genet. 2008 Apr;46(3-4):137-44 [18210196.001]
  • (PMID = 19562509.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


22. Wang DC, Wang LD, Zheng S, Fan ZM, Li JL, Feng CW, Zhang YR, Liu B, Gao SS, He X: [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):573-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma].
  • OBJECTIVES: To evaluate the serum biomarkers for diagnosis of gastric cardia dysplasia (DYS) and chronic atrophic gastric-carditis (CAG) and to provide a novel screening method for high risk population of gastric-cardia adenocarcinoma (GCA).
  • A set of spectra derived from analysis of serum from 143 symptom-free subjects at high-risk area for GCA, including 63 cases with histologically normal gastric cardia epithelia, 57 of CAG and 23 of DYS, were analyzed by bioinformatics like decision tree classification algorithm.
  • CONCLUSIONS: The gastric cardia lesions of DYS and CAG could be identified by SELDI-TOF-MS technique specifically in symptom-free subjects at high incidence area for GCA.
  • [MeSH-major] Biomarkers, Tumor / blood. Cardia. Gastritis, Atrophic / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194406.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Ryan AM, Rowley SP, Fitzgerald AP, Ravi N, Reynolds JV: Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity. Eur J Cancer; 2006 May;42(8):1151-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity.
  • Recent evidence links obesity with the rising incidence of oesophageal adenocarcinoma.
  • In Ireland between 1995 and 2004 the incidence of oesophageal adenocarcinoma increased by 38%, and this coincided with a 67% increase in the prevalence of obesity.
  • In this study, a prospective case-control study was undertaken in 760 patients presenting to a tertiary centre between 1994 and 2004 diagnosed with cancer of the oesophagus, gastric cardia or stomach.
  • Based on pre-illness BMI, 82% of patients who developed adenocarcinoma of the oesophagus were either overweight or obese compared with 59% of the healthy control population (P<0.001).
  • A dose-dependent relationship existed between BMI and oesophageal adenocarcinoma in males.
  • Using common cut-off points for BMI, the OR of adenocarcinoma of the lower oesophagus was 11.3 times higher (95% CI: 3.5-36.4) for individuals with a BMI >30 kg/m2 versus individuals with a BMI <22 kg/m2 (P<0.001 for trend).
  • For adenocarcinoma of the gastric cardia, males in the top quartile of BMI had an OR of 3.5 (95% CI: 1.3-9.4) compared with the lowest quartile (P=0.03 for trend).
  • The odds ratio for adenocarcinoma of the oesophagus, the oesophago-gastric junction and gastric cardia rose significantly with increasing BMI.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Cardia. Esophageal Neoplasms / etiology. Obesity / complications. Stomach Neoplasms / etiology


24. Jin L, Yoshida M, Kitagawa Y, Saikawa Y, Takeuchi H, Wada N, Kumai K, Kubota T, Kitajima M: Subclassification of superficial cardia cancer in relation to the endoscopic esophagogastric junction. J Gastroenterol Hepatol; 2008 Dec;23 Suppl 2:S273-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclassification of superficial cardia cancer in relation to the endoscopic esophagogastric junction.
  • BACKGROUND: The incidence of adenocarcinoma of the gastric cardia has been reported to be increasing, but the endoscopic characteristics of the mucosal background of the tumor remain unclear.
  • The purpose of the present study was to evaluate the relationship between the location of the adenocarcinoma according to the esophagogastric junction (EGJ) and mucosal characteristics.
  • METHODS: Patients with superficial adenocarcinoma of the gastric cardia diagnosed pathologically were enrolled and divided into the above-EGJ group and the below-EGJ group according to tumor location.
  • We retrospectively reviewed endoscopic findings with respect to the classification of reflux esophagitis, hiatus hernia, valvular appearance of the cardia and the pattern of atrophic gastritis.
  • The severity of hiatus hernia and the valvular appearance of the cardia of patients in the above-EGJ group were worse than in the patients in the below-EGJ group.
  • CONCLUSION: There were significant differences between cancers above or below the EGJ, so classification of adenocarcinoma of the gastric cardia according to location is recommended.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Endoscopy, Gastrointestinal. Esophagogastric Junction. Gastric Mucosa / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120911.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


25. Lindblad M, Rodríguez LA, Lagergren J: Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control; 2005 Apr;16(3):285-94
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study.
  • OBJECTIVES: To prospectively assess the influence of body mass index (BMI), tobacco, and alcohol on the occurrence of esophageal, gastric cardia, and non-cardia gastric adenocarcinoma, and to detect any sex differences that could explain the male predominance of these tumors.
  • RESULTS: During follow-up of 4,340,207 person-years, we identified 287 esophageal adenocarcinomas, 195 gastric cardia adenocarcinomas, 327 gastric non-cardia adenocarcinomas, and 10,000 controls.
  • A positive association was found between overweight (BMI > 25 kg/m(2)) and esophageal adenocarcinoma (OR 1.67, 95% CI 1.22--2.30), and gastric cardia adenocarcinoma (OR 1.46, 95% CI 0.98--2.18), but not non-cardia gastric adenocarcinoma.
  • The association between BMI and esophageal and gastric cardia adenocarcinoma were dose-dependent and seemingly independent of reflux.
  • CONCLUSIONS: Overweight increases risk of esophageal and gastric cardia adenocarcinoma, while tobacco smoking increases risk of esophageal, gastric cardia, and non-cardia gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Alcohol Drinking / adverse effects. Body Mass Index. Cardia / pathology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / etiology. Smoking / adverse effects. Stomach Neoplasms / epidemiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947880.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Carneiro F, Chaves P: Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction. Surg Oncol Clin N Am; 2006 Oct;15(4):697-714
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction.
  • Available evidence supports the existence of two major pathways of neoplastic development in the gastroesophageal region: the Barrett pathway, related to gastroesophageal reflux disease, and the gastric pathway, related to Helicobacter pylori infection.
  • The existence of an independent junctional pathway is questionable, and gastroesophageal junction adenocarcinomas share features of esophageal and gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030268.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 120
  •  go-up   go-down


27. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA: Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut; 2007 Nov;56(11):1503-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study.
  • BACKGROUND: In the last decades, the incidence of oesophageal and gastric cardia adenocarcinoma has increased rapidly in the Western world.
  • We investigated the association between body mass index (BMI), height and risk of oesophageal and gastric cardia adenocarcinoma.
  • After 13.3 years of follow-up, excluding the first follow-up year, complete data from 4552 subcohort members, 133 oesophageal and 163 gastric cardia adenocarcinomas were available for case-cohort analyses.
  • RESULTS: The RRs (95% CI) of oesophageal adenocarcinoma were 1.40 (0.95 to 2.04) and 3.96 (2.27 to 6.88) for overweight (BMI 25.0-29.9 kg/m(2)) and obese subjects (BMI >or=30.0 kg/m(2)), respectively, compared to subjects with normal weight (BMI 20.0-24.9 kg/m(2)).
  • For gastric cardia adenocarcinoma, these RRs were 1.32 (0.94 to 1.85) and 2.73 (1.56 to 4.79).
  • Also change in BMI during adulthood was positively associated with the risk of oesophageal and gastric cardia adenocarcinoma (p trend 0.001 and 0.02, respectively), while no association was found with BMI in early adulthood (p trend 0.17 and 0.17, respectively).
  • CONCLUSIONS: These results confirm higher risks of oesophageal and gastric cardia adenocarcinoma with increasing BMI.
  • This implies that the increasing prevalence of obesity may be one of the explanations for the rising incidence of oesophageal and gastric cardia adenocarcinoma in the Western world.
  • [MeSH-major] Adenocarcinoma / etiology. Body Height / physiology. Cardia. Esophageal Neoplasms / etiology. Obesity / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):975-9 [11521805.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] Int J Obes Relat Metab Disord. 2002 Sep;26(9):1218-24 [12187399.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):269-70 [12397649.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] Int J Epidemiol. 2003 Aug;32(4):645-50 [12913045.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] Am J Clin Nutr. 1981 Aug;34(8):1593-9 [7270483.001]
  • [Cites] Am J Epidemiol. 1982 Feb;115(2):223-30 [7058781.001]
  • [Cites] J Clin Epidemiol. 1990;43(3):285-95 [2313318.001]
  • [Cites] Int J Epidemiol. 1990 Sep;19(3):553-8 [2262247.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Epidemiology. 1990 Mar;1(2):146-52 [2073502.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):369-77 [9149898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Eur J Cancer Prev. 1999 Apr;8(2):115-22 [10335457.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1167-75 [15561645.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [CommentIn] Gut. 2007 Nov;56(11):1493-4 [17938426.001]
  • (PMID = 17337464.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2095659
  •  go-up   go-down


28. Wen D, Shan B, Wang S, Zhang L, Wei L, Zhou W, Peng Q: A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area. Eur J Med Genet; 2010 Sep-Oct;53(5):250-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area.
  • BACKGROUND: To find a genetic component in gastric cardia adenocarcinomas (GCA).
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group. Cardia / pathology. Esophageal Neoplasms / genetics. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20603233.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH: Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol; 2006 Jun 28;12(24):3883-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia.
  • AIM: To investigate the influence of a positive proximal margin in total gastrectomy patients with gastric adenocarcinoma of the cardia.
  • METHODS: Medical records of 191 patients with total gastrectomies for adenocarcinoma of the cardia between 1995 and 2000 were reviewed.
  • CONCLUSION: A positive margin is more of an indication of advanced disease in patients with gastric adenocarcinoma of the cardia rather than an independent prognostic factor for survival.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cardia / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1977 Apr;144(4):563-6 [847612.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] Am J Surg. 1980 May;139(5):711-3 [7468923.001]
  • [Cites] Ann Surg. 1982 Dec;196(6):685-90 [7149820.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10):700-3 [11021482.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1773-6 [11037842.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):810-4 [11087650.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):588-93 [12943624.001]
  • [Cites] Curr Probl Surg. 1973 Nov;:3-72 [4592910.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):247-50 [3629439.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1347-51 [3675199.001]
  • [Cites] J Surg Oncol. 1989 Mar;40(3):162-9 [2465454.001]
  • [Cites] Ann Acad Med Singapore. 1989 Jan;18(1):69-71 [2712522.001]
  • [Cites] J Surg Oncol. 1989 Nov;42(3):170-4 [2811381.001]
  • [Cites] Acta Chir Scand. 1990 Feb;156(2):127-30 [2330791.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):60-3 [8479199.001]
  • [Cites] Br J Surg. 1993 Nov;80(11):1418-20 [8252353.001]
  • [Cites] Am J Surg. 1995 Mar;169(3):316-9 [7879834.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):873-7 [8847038.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):433-7 [8814687.001]
  • [Cites] Aust N Z J Surg. 1996 Nov;66(11):734-7 [8918379.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Surg. 1981 Feb;68(2):73-4 [7459624.001]
  • (PMID = 16804975.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087938
  •  go-up   go-down


30. Falk J, Carstens H, Lundell L, Albertsson M: Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences. Acta Oncol; 2007;46(8):1070-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences.
  • BACKGROUND: The incidence of adenocarcinoma of the oesophagus is rising in many western countries including Sweden.
  • METHODS: We have studied the latest data concerning this as well as trends in the incidence of squamous cell carcinoma and adenocarcinoma of gastric cardia.
  • RESULTS: The results show an increasing incidence of adenocarcinoma in both oesophagus and gastric cardia.
  • Adenocarcinoma is now the most common histological type of cancer in the oesophageal/cardia region in Sweden.
  • Results also suggest a possible drift in location of adenocarcinoma from gastric cardia towards oesophagus.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851842.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


31. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y, Fujii S, Akiyama H, Nomura M, Otsuka Y, Ono HA, Kosaka T, Takagawa R, Ichikawa Y, Shimada H: Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg; 2007 Aug;11(8):1039-44
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of splenectomy in patients with gastric adenocarcinoma of the cardia.
  • Previous reports have suggested that splenectomy treatment of gastric carcinoma of the cardia results in poor patient outcome, but the reason for this is unclear.
  • This study aimed to clarify the impact of splenectomy for gastric carcinoma patients.
  • A total of 118 patients with gastric carcinoma of the cardia were enrolled in this study.
  • Splenectomy should be limited in those patients with gastric cardia tumors invading the spleen or with metastatic bulky lymph nodes extending to the spleen.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Splenectomy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Surgery. 1996 Jul;120(1):40-4 [8693421.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Surgery. 1994 Nov;116(5):837-41 [7940186.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):718-26 [16713545.001]
  • [Cites] Surgery. 2002 Apr;131(4):401-7 [11935130.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):682-9 [15231523.001]
  • [Cites] J Surg Oncol. 2006 Apr 1;93(5):394-400 [16550575.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5b):4181-6 [14666622.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):119-22 [10027374.001]
  • [Cites] J Am Coll Surg. 1997 Aug;185(2):177-84 [9249086.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):346-51 [7796005.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):89-92 [11223832.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):46-56 [10030415.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3006-9 [2044047.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):359-64 [1998479.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):402-6 [11407513.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):659-67 [16538414.001]
  • [Cites] Br J Surg. 2006 May;93(5):559-63 [16607678.001]
  • (PMID = 17514409.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, Tsujii S, Onishi S, Kobayashi M, Hanazaki K: Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg; 2008 Feb;206(2):306-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach?
  • BACKGROUND: Although the incidence of gastric cardia cancer is considerably less than more distal gastric cancer, the rate of occurrence is now increasing.
  • The objective of this study was to evaluate and compare the clinicopathologic findings of gastric cardia and more distal stomach adenocarcinoma.
  • STUDY DESIGN: Patients included in our study were those who underwent operations for gastric adenocarcinoma in our institute from 1981 to 2006, and who had undergone complete medical history, including history of daily alcohol consumption; smoking; body mass index; and pathologic examinations.
  • A total of 843 patients were included in our study, and were divided into cardia and noncardia cancer groups.
  • RESULTS: Among the 843 patients, 23 (2.8%) had gastric cardia cancer.
  • Mean size of cardia tumors was larger than noncardia tumors.
  • Although noncardia cancer was often detected at an early stage, gastric cardia cancer was most often diagnosed at an advanced stage.
  • Pathologically, cardia cancer was more invasive and had more lymphatic permeation and lymph node metastasis than noncardia cancer.
  • CONCLUSIONS: Gastric cardia cancer occurs at a low incidence of only 2.8% of resected gastric cancers.
  • Unlike cases of gastric cardia cancer in Western populations, body mass index is not associated with occurrence of gastric cardia cancer in our study.
  • Because gastric cardia cancer appears more aggressive than noncardia gastric cancer, early diagnosis and intervention are important.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222384.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Parfitt JR, Miladinovic Z, Driman DK: Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002. Can J Gastroenterol; 2006 Apr;20(4):271-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002.
  • BACKGROUND: The increasing incidence of esophageal and proximal gastric (cardia) adenocarcinoma and the decreasing incidence of distal gastric (antropyloric) adenocarcinoma has been documented in several populations.
  • Number of cases and rates per 100,000 age-adjusted to the 1996 Canadian standard, were obtained for all esophageal and gastric carcinoma cases reported between 1964 and 2002.
  • RESULTS: The incidence of adenocarcinoma of the distal esophagus increased in men and women (average annual increase of 9.5% in men; 4.3% in women).
  • The incidence of adenocarcinoma of the cardia increased in men and women (average annual increase of 7.3% in men; 5.8% in women).
  • The incidence of antropyloric adenocarcinoma increased in men and women (average annual increase of 4.4% in men; 5.3% in women).
  • CONCLUSIONS: There has been a significant increase in the incidence of adenocarcinoma around the gastroesophageal junction in men over the 39-year study period.
  • The increase in incidence of distal gastric adenocarcinoma is unexpected and may relate to a reclassification phenomenon, immigration trends in Ontario and a rising incidence of diffuse/signet ring cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Esophagogastric Junction. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1082-6 [11099062.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):290 [15737017.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Can J Public Health. 2004 Jan-Feb;95(1):16-20 [14768735.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] BMJ. 2004 Aug 21;329(7463):420 [15321897.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):275-8 [1467774.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):411-5 [7841063.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Prev Med. 1997 Jul-Aug;26(4):534-41 [9245676.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Health Rep. 1998 Spring;9(4):31-7(Eng); 31-8(Fre) [9836878.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Apr;13(4):356-62 [9641297.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • (PMID = 16609756.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2659904
  •  go-up   go-down


34. Jansson C, Johansson AL, Bergdahl IA, Dickman PW, Plato N, Adami J, Boffetta P, Lagergren J: Occupational exposures and risk of esophageal and gastric cardia cancers among male Swedish construction workers. Cancer Causes Control; 2005 Aug;16(6):755-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposures and risk of esophageal and gastric cardia cancers among male Swedish construction workers.
  • OBJECTIVE: The rising incidence and the strong male predominance among patients with esophageal and gastric cardia adenocarcinoma remain unexplained.
  • RESULTS: We found positive associations between high exposure to asbestos (IRR 4.5 [95% CI 1.4-14.3]) and cement dust (IRR 3.8 [95% CI 1.5-9.6]) and risk of esophageal adenocarcinoma.
  • Associations were seen between high exposure to asphalt fumes (IRR 2.3 [95% CI 1.0-5.3]) and wood dust (IRR 4.8 [95% CI 1.2-19.4]) and risk of cardia adenocarcinoma.
  • CONCLUSIONS: Exposure to asbestos and cement dust may be risk factors for esophageal adenocarcinoma, and exposure to asphalt fumes and wood dust may increase the risk of cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia / pathology. Construction Materials. Esophageal Neoplasms / etiology. Occupational Exposure / adverse effects. Stomach Neoplasms / etiology


35. Koshiol J, Wei WQ, Kreimer AR, Ren JS, Gravitt P, Chen W, Kim E, Abnet CC, Zhang Y, Kamangar F, Lin DM, Wang GQ, Roth MJ, Dong ZW, Taylor PR, Qiao YL, Dawsey SM: The gastric cardia is not a target for human papillomavirus-induced carcinogenesis. Cancer Epidemiol Biomarkers Prev; 2010 Apr;19(4):1137-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gastric cardia is not a target for human papillomavirus-induced carcinogenesis.
  • BACKGROUND: Thousands of people in central Asia die every year from gastric cardia adenocarcinoma (GCA).
  • GCA arises in the transformation zone between the esophagus and the stomach, similar to cervical and oropharyngeal carcinoma, which arise in areas with transformation zone characteristics.
  • The analogous biology of the gastric cardia to the cervix and oropharynx, where human papillomavirus (HPV) is known to cause cancer, raises the possibility that GCA could be a HPV-associated cancer.
  • CONCLUSIONS: These results suggest that HPV does not contribute to gastric cardia carcinogenesis in north central China.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Infect. 1999 Oct;75(5):317-9 [10616355.001]
  • [Cites] Int J Cancer. 2010 Jul 1;127(1):93-100 [19918949.001]
  • [Cites] Sex Transm Infect. 2002 Apr;78(2):135-8 [12081177.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2003 Nov 10;83(21):1910-4 [14642078.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3176-84 [15243079.001]
  • [Cites] J Med Virol. 2004 Sep;74(1):107-16 [15258976.001]
  • [Cites] N Engl J Med. 1986 Oct 23;315(17):1089-90 [3020406.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):950-4 [2555753.001]
  • [Cites] J Infect Dis. 1997 Oct;176(4):1076-9 [9333171.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):3020-7 [9738060.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):579-84 [16496409.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):885-91 [17131323.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):621-32 [17405118.001]
  • [Cites] J Clin Microbiol. 2000 Jan;38(1):357-61 [10618116.001]
  • (PMID = 20332262.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / N01RC47702; United States / Intramural NIH HHS / / Z99 CA999999; United States / CCR NIH HHS / RC / N01-RC-47702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS179295; NLM/ PMC2852466
  •  go-up   go-down


36. He YT, Hou J, Chen ZF, Qiao CY, Song GH, Meng FS, Jin HX, Chen C: Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China. Eur J Cancer Prev; 2008 Apr;17(2):71-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China.
  • Incidence rates have risen for gastric cardia adenocarcinoma, whereas rates have remained stable for esophageal squamous cell carcinoma in many western countries.
  • The aim of this study was to describe and analyze trends in incidence rates for esophageal cancer and gastric cardia cancer in Cixian county, which is one of the high-risk areas for esophageal cancer in China as well as in the world.
  • For gastric cardia cancer, there were 1654 cases from 1988 to 2003.
  • A statistically significant increasing trend of gastric cardia cancer was observed during the study period.
  • Cixian county is a geographical region with a very high incidence of esophageal cancer and cardia cancer.
  • The trend in the incidence rates of esophageal cancer had decreased slightly; on the other hand, gastric cardia cancer showed a significantly increased trend in the last 16 years.
  • [MeSH-major] Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287862.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Ding GC, Ren JL, Chang FB, Li JL, Yuan L, Song X, Zhou SL, Guo T, Fan ZM, Zeng Y, Wang LD: Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers. World J Gastroenterol; 2010 Dec 14;16(46):5901-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers.
  • AIM: To investigate the relationship between human papillomavirus (HPV) infection and concurrent esophagus and gastric cardia cancer from the same patient (CC) and examine the significance of P16(INK4A) protein expression.
  • RESULTS: Among the CC specimens, HPV16-DNA was found in eight cases of esophageal squamous cell carcinoma (ESCC) and five cases of gastric cardia adenocarcinoma (GCA), respectively (47% vs 29%), and two of both ESCC and GCA.
  • P16(INK4A) may be a screening index in the HPV-associated carcinoma of gastric cardia.
  • [MeSH-major] Cardia / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / genetics. Esophageal Neoplasms / virology. Human papillomavirus 16 / genetics. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):874-8 [10842204.001]
  • [Cites] Dis Esophagus. 2004;17(1):10-26 [15209736.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):929-34 [11375901.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):16-21 [12508343.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1170-3 [12800217.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2003 Nov 10;83(21):1910-4 [14642078.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Diagn Histopathol. 1982 Oct-Dec;5(4):291-6 [6188592.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1554-9 [17453003.001]
  • [Cites] Mol Carcinog. 2008 Feb;47(2):100-4 [17918207.001]
  • [Cites] Magy Seb. 2008 Aug;61(4):225-9 [18799406.001]
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Aug;22(4):251-3 [19105334.001]
  • [Cites] J BUON. 2009 Jul-Sep;14(3):495-9 [19810144.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1137-9 [20332262.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Nov;126(11):655-60 [11079730.001]
  • (PMID = 21155014.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC3001984
  •  go-up   go-down


38. Fan YJ, Song X, Li JL, Li XM, Liu B, Wang R, Fan ZM, Wang LD: Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period. World J Surg; 2008 Sep;32(9):1980-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period.
  • BACKGROUND: Nutrition deficiencies or poverty traditionally have been recognized to be related with increased risk for esophageal cancer (EC) in rural regions at junction of Henan, Hebei, and Shanxi provinces in northern China--the highest incidence area for esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA).
  • However, the histopathological types, staging pattern, and occurrence of ESCC and GCA, especially for esophageal adenocarcinoma (EAC), which have been rarely examined in the Chinese population during the past decades in these areas have not been well characterized to date.
  • The present results demonstrate the difference in municipal and rural regions of ESCC, ECA, and GCA in histopathological types, and suggest that there may be different etiological factors involved in esophageal and gastric cardia carcinogenesis in these different areas.
  • [MeSH-major] Cardia / pathology. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Chi-Square Distribution. China / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Risk Factors. Rural Population. Urban Population

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1231-7 [11677937.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):702-6 [9125635.001]
  • [Cites] J Natl Cancer Inst. 1984 Dec;73(6):1449-53 [6595453.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 May;16(5):495-501 [15097043.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4342-6 [8044781.001]
  • [Cites] Z Gastroenterol. 1982 Jul;20(7):361-7 [7051590.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):513-29 [15297943.001]
  • [Cites] Dis Esophagus. 2006;19(6):477-81 [17069592.001]
  • [Cites] Ecol Dis. 1983;2(4):249-53 [6681155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:159-72 [11890101.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):398-407 [16616342.001]
  • [Cites] Hum Nutr Clin Nutr. 1982;36(5):337-49 [7174357.001]
  • [Cites] Cancer. 1992 May 1;69(9):2227-31 [1562967.001]
  • [Cites] Nutr Cancer. 1985;7(3):131-43 [3878498.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Mar;15(3):230-8 [10764021.001]
  • [Cites] Am J Gastroenterol. 1998 May;93(5):702-5 [9625112.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):514-9 [7960222.001]
  • [Cites] Crit Rev Oncol Hematol. 1987;7(4):267-87 [3322593.001]
  • [Cites] Dig Dis Sci. 2002 Apr;47(4):735-40 [11991601.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Dec;22(12):1164-71 [9877251.001]
  • [Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1783-7 [8467496.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jan-Feb;2(1):71-8 [8420615.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):259-64 [1467771.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Dec;16(12):2037-42 [12452935.001]
  • [Cites] Am Fam Physician. 2006 Jun 15;73(12):2187-94 [16836035.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S22-5 [15324378.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):405-6 [9162308.001]
  • [Cites] J Gastroenterol. 2003 Mar;38 Suppl 15:25-30 [12698867.001]
  • [Cites] Ann Ist Super Sanita. 1996;32(1):65-72 [8804186.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Nutr Cancer. 1982;4(2):154-64 [7162996.001]
  • [Cites] Cancer Res. 1980 Aug;40(8 Pt 1):2633-44 [6992989.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):77-84 [9934853.001]
  • [Cites] J Gastroenterol. 2003 Mar;38 Suppl 15:3-6 [12698863.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1647-51 [15162542.001]
  • (PMID = 18566857.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Wang LD, Guo RF, Fan ZM, He X, Gao SS, Guo HQ, Matsuo K, Yin LM, Li JL: Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population. Dis Esophagus; 2005;18(3):177-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population.
  • To investigate the association between these polymorphisms and the risk of esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA), we conducted a case-control study in the Anyang area where the incidence of ESCC is highest in northern China.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045580.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 65871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


40. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y: Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol; 2010 Mar;25(3):555-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
  • This study was designed to investigate the correlation of FAS-1377 G/A, -670 A/G and FASL-844 T/C polymorphisms with susceptibility to gastric cardiac adenocarcinoma in a population of a high-incidence region of Hebei Province.
  • METHODS: FAS-1377 G/A, -670 A/G and FASL-844 T/C polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism analysis in 262 gastric cardiac carcinoma (GCA) patients and 524 healthy controls.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, CD95 / genetics. Biomarkers, Tumor / genetics. Cardia. Fas Ligand Protein / genetics. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074157.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / Fas Ligand Protein
  •  go-up   go-down


41. Miao X, Zhang X, Zhang L, Guo Y, Hao B, Tan W, He F, Lin D: Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology; 2006 Aug;131(2):420-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer.
  • This study examined the effects of ADPRT Val762Ala and XRCC1 Arg399Gln polymorphisms on ADPRT-XRCC1 interaction in vitro in cells and their contributions to gastric cardia adenocarcinoma (GCA) risk.
  • [MeSH-major] ADP Ribose Transferases / genetics. Cardia / pathology. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890595.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 2.4.2.- / ADP Ribose Transferases
  •  go-up   go-down


42. Tangen M, Andresen SJ, Moum B, Hauge T: [Stent insertion as palliation of cancer in the esophagus and cardia]. Tidsskr Nor Laegeforen; 2006 Jun 8;126(12):1607-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stent insertion as palliation of cancer in the esophagus and cardia].
  • [Transliterated title] Palliasjon med stent ved kreft i oesophagus og cardia.
  • BACKGROUND: The insertion of self-expanding metal stents (SEMS) for palliation of dysphagia in patients with malignant stenosis of the esophagus and cardia, is a well-established procedure.
  • CONCLUSION: Insertion of SEMS in patients with inoperable carcinoma in esophagus and cardia should be regarded as a safe procedure.
  • [MeSH-major] Cardia. Esophageal Neoplasms / therapy. Palliative Care / methods. Stents. Stomach Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Deglutition Disorders / etiology. Deglutition Disorders / therapy. Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Esophagoscopy. Female. Humans. Male. Metals. Middle Aged. Prosthesis Implantation / adverse effects. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770371.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


43. Gregersen LH, Friis S, Olsen JH: [Cancer in esophagus and cardia--incidence trends in Denmark]. Ugeskr Laeger; 2008 Apr 21;170(17):1460-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer in esophagus and cardia--incidence trends in Denmark].
  • [Transliterated title] Kraeft i øsofagus og cardia--incidensudvikling i Danmark.
  • INTRODUCTION: The incidence of adenocarcinoma in esophagus and cardia has been reported as increasing in a number of countries over recent decades.
  • The study evaluates the incidence trends for esophagus- and stomach cancer in the period 1943-2003 with focus on changes since 1978.
  • The corresponding incidence rate for stomach cancer decreased over the entire study period from 21.9 per 100,000 in 1943-1947 to 9.7 per 100,000 in 1998-2003.
  • During the period 1978-2003 we observed a marked decrease in the incidence of adenocarcinoma in the distal stomach, whereas the incidence of adenocarcinoma in the cardia was constant in this period.
  • CONCLUSION: The incidence of esophageal adenocarcinoma has increased during the past 25 years in Denmark, whereas the incidence of adenocarcinoma in the cardia has remained constant.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462626.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


44. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A: A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer; 2008 Feb;44(3):465-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma (EADC) is rapidly increasing in Western countries and obesity is thought to be a major risk factor.
  • We examined the association between BMI and EADC, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in a cohort of approximately 500,000 people in the United States (US).
  • We found that compared to people with a BMI of 18.5-25kg/m2, a BMI > or = 35 was associated with significantly increased risk of EADC, HR (95% CI)=2.27 (1.44-3.59) and gastric cardia adenocarcinoma 2.46 (1.60-3.80), but not gastric non-cardia adenocarcinoma 0.84 (0.50-1.42).
  • [MeSH-major] Adenocarcinoma / etiology. Attitude to Health. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):319-23 [3856045.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • (PMID = 18221867.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS42480; NLM/ PMC2350215
  •  go-up   go-down


45. Younes M: What is the role of cytokeratins in Barrett/cardia differentiation? Arch Pathol Lab Med; 2005 Feb;129(2):181-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the role of cytokeratins in Barrett/cardia differentiation?
  • The importance of distinguishing between Barrett metaplasia and intestinal metaplasia of the gastric cardia is now accepted, and the management of each entity is quite different.
  • Patients with Barrett metaplasia are enrolled in surveillance programs, consisting of periodic endoscopy and biopsy, because of the known risk of developing adenocarcinoma of the esophagus.
  • Patients with intestinal metaplasia of the gastric cardia, however, are not currently enrolled in such programs, because this condition carries a low risk of developing adenocarcinoma of the gastric cardia.
  • However, because it may be associated with premalignant lesions elsewhere in the gastric mucosa, we propose that intestinal metaplasia of the gastric cardia may have the same clinical implication as Barrett metaplasia.
  • [MeSH-major] Barrett Esophagus / etiology. Cardia / pathology. Keratins / physiology. Metaplasia / etiology. Stomach Diseases / etiology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679416.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 68238-35-7 / Keratins
  • [Number-of-references] 16
  •  go-up   go-down


46. Ridereau-Zins C, Lebigot J, Moubarak E, Hamy A, Azoulay R, Aubé C: [Postoperative imaging of the cardia and stomach]. J Radiol; 2009 Jul-Aug;90(7-8 Pt 2):937-53
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative imaging of the cardia and stomach].
  • [Transliterated title] Imagerie post-opératoire du cardia et de l'estomac.
  • In addition to treatment of complications from peptic ulcer disease, gastroesophageal reflux and gastric cancer, bariatric surgical procedures have increased over the recent years.
  • Complications after gastric surgery are imaged with upper gastrointestinal contrast studies and CT.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Cardia / surgery. Fundoplication. Gastrectomy. Gastroesophageal Reflux / surgery. Gastroplasty. Postoperative Complications / radiography. Stomach / surgery. Stomach Neoplasms / radiography. Stomach Neoplasms / surgery. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Anastomosis, Surgical / adverse effects. Contrast Media. Gastric Bypass. Gastric Fistula / etiology. Gastroenterostomy. Humans. Lymph Node Excision. Male. Pancreas / surgery. Spleen / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752832.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 30
  •  go-up   go-down


47. Abnet CC, Fan JH, Kamangar F, Sun XD, Taylor PR, Ren JS, Mark SD, Zhao P, Fraumeni JF Jr, Qiao YL, Dawsey SM: Self-reported goiter is associated with a significantly increased risk of gastric noncardia adenocarcinoma in a large population-based Chinese cohort. Int J Cancer; 2006 Sep 15;119(6):1508-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-reported goiter is associated with a significantly increased risk of gastric noncardia adenocarcinoma in a large population-based Chinese cohort.
  • Iodine is concentrated by the gastric mucosa, where it may act as an antioxidant.
  • Therefore, iodine deficiency, and its sequelae goiter, may be associated with an increased risk of gastric cancer.
  • Using multivariate adjusted Cox models, we found goiter associated with a significantly increased risk of gastric noncardia adenocarcinoma, HR (95% CI) 2.04 (1.01, 4.11) and nonsignificantly with gastric cardia adenocarcinoma, HR (95% CI) 1.45 (0.91, 2.30).
  • Our findings are consistent with the hypothesis that iodine deficiency is associated with an increased risk of gastric cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Goiter / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642482.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


48. Wu AH, Tseng CC, Hankin J, Bernstein L: Fiber intake and risk of adenocarcinomas of the esophagus and stomach. Cancer Causes Control; 2007 Sep;18(7):713-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fiber intake and risk of adenocarcinomas of the esophagus and stomach.
  • BACKGROUND: Since the 1970s, incidence rates for esophageal and gastric cardia adenocarcinomas have risen substantially for reasons that are not well understood.
  • METHODS: This analysis on dietary factors included 206 esophageal adenocarcinoma, 257 gastric cardia, 366 distal gastric adenocarcinoma patients and, 1,308 control subjects from a population-based, case-control study conducted in Los Angeles County.
  • RESULTS: Intake of fiber had a significant impact on risk of esophageal and gastric cardia adenocarcinoma after adjustment for age, gender, race, birthplace, education, cigarette smoking, body size, history of reflux, and vitamin use.
  • Compared to subjects in the lowest quartile of fiber intake, subjects in the highest quartile of intake showed odd ratios of 0.44 (95% CI = 0.26-0.76) for esophageal adenocarcinoma (P trend = 0.004) and 0.58 (95% CI = 0.38-0.88) for gastric cardia adenocarcinoma (P trend = 0.016); these inverse associations remained after further adjustment for intake of fat.
  • For distal gastric cancer, a significant inverse association with fiber was observed only after adjustment for fat intake.
  • CONCLUSIONS: High intake of fiber was associated with significant reduced risks of esophageal and gastric cardia adenocarcinoma even after adjustment for dietary fat, H. pylori infection and other covariates.
  • [MeSH-major] Adenocarcinoma / etiology. Dietary Fiber / pharmacology. Eating / physiology. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562192.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 5P30 ES07048; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CN / N01CN25403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


49. Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC: Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol; 2008 May 28;14(20):3165-73
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma.
  • METHODS: The US National Cancer Institutes' Patterns of Care study was used to examine therapies and survival of patients diagnosed in 2001 with histologically-confirmed gastroesophageal adenocarcinoma (n = 1356).
  • RESULTS: Approximately 62% of patients had stomach adenocarcinoma (SAC), while 22% had gastric-cardia adenocarcinoma (GCA), and 16% lower esophageal adenocarcinoma (EAC).
  • Stage IV/unstaged esophageal cancer patients were most likely and stage I-III stomach cancer patients least likely to receive chemotherapy as all or part of their therapy; gastric-cardia patients received chemotherapy at a rate between these two.
  • Among esophageal and stomach cancer patients, receipt of chemotherapy was associated with lower mortality; but no association was found among gastric-cardia patients.
  • Findings suggest that physicians treat lower esophageal and SAC as two distinct entities, while gastric-cardia patients receive a mix of the treatment strategies employed for the two other sites.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2005 May;41(7):1051-7 [15862755.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):419-24 [15816605.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 May-Jun;28(3):284-8 [15886931.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):73-81 [16170828.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):204-13 [16482619.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2308-18 [17032196.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1089-98 [17369572.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):546-52 [17372250.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1223-33 [10725635.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):387-90 [10917556.001]
  • [Cites] Cancer J. 2000 Sep-Oct;6(5):316-23 [11079171.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):338-56 [11260097.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1192-202 [11870160.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):210-4 [11888881.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3488-94 [12972525.001]
  • [Cites] Dis Esophagus. 2003;16(3):270-2 [14641325.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):42-50 [14698310.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):338-45 [14760131.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):737-41 [14999783.001]
  • [Cites] Oncologist. 2004;9(2):147-59 [15047919.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):214-21 [15501461.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Ann Thorac Surg. 1996 Jan;61(1):190-4 [8561551.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1423-7 [9146337.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):25-33 [9655289.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):162-9 [10450729.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3270-5 [10506629.001]
  • [Cites] Ann Thorac Surg. 2005 Feb;79(2):391-7; discussionn 391-7 [15680801.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2325-31 [15800323.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):166-70 [15895449.001]
  • (PMID = 18506920.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01PC35143; United States / NCI NIH HHS / CA / N01PC35138; United States / NCI NIH HHS / CA / N01PC35141; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CA / N01PC35133; United States / NCI NIH HHS / CA / N01PC35142; United States / NCI NIH HHS / CA / N01PC35135; United States / NCI NIH HHS / CA / N01PC35145; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2712847
  •  go-up   go-down


50. Liu JF, Jamieson GG, Wu TC, Zhu GJ, Drew PA: A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol; 2009 May;16(5):1397-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
  • BACKGROUND: We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia.
  • There was a significant improvement in survival for patients with adenocarcinoma of the cardia on aspirin compared with the two control groups combined (P = 0.029).
  • However, there was no significant difference between the survival curves for T2N0M0 adenocarcinoma patients on aspirin (21) and the two control groups combined (65) (P = 0.29).
  • [MeSH-major] Adenocarcinoma / drug therapy. Aspirin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cyclooxygenase 2 Inhibitors / administration & dosage. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cardia. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241108.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; R16CO5Y76E / Aspirin; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ: Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol; 2005 Dec 1;92(3):160-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the EGJ can be categorized in two types of cancer divided according to their anatomical origin: distal esophageal adenocarcinoma and adenocarcinoma of the gastric cardia.
  • However, due to their location, in the transitional zone of the esophagus and stomach, there is constant debate about the proper classification, staging, and management of these tumors.
  • The etiology of distal esophageal adenocarcinoma is clearly related to gastroesophageal reflux disease (GERD) and the development of a Barrett's esophagus [2].
  • The etiology of adenocarcinoma of the gastric cardia is less well understood.
  • Special attention will be given to differences and similarities of adenocarcinomas of the gastric cardia and distal esophagus.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms
  • [MeSH-minor] Barrett Esophagus / complications. Diagnosis, Differential. Diet. Gastric Mucosa / pathology. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Metaplasia. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16299781.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


52. García Rodríguez LA, Lagergren J, Lindblad M: Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut; 2006 Nov;55(11):1538-44
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
  • BACKGROUND: Gastric acid suppressing drugs (that is, histamine(2) receptor antagonists and proton pump inhibitors) could affect the risk of oesophageal or gastric adenocarcinoma but few studies are available.
  • AIMS: To study the association between long term treatment with acid suppressing drugs and the risk of oesophageal or gastric adenocarcinoma.
  • RESULTS: In 4 340 207 person years of follow up, 287 patients with oesophageal adenocarcinoma, 195 with gastric cardia adenocarcinoma, and 327 with gastric non-cardia adenocarcinoma were identified, and 10 000 control persons were randomly sampled.
  • "Oesophageal" indication for long term acid suppression (that is, reflux symptoms, oesophagitis, Barrett's oesophagus, or hiatal hernia) rendered a fivefold increased risk of oesophageal adenocarcinoma (odds ratio (OR) 5.42 (95% confidence interval (CI) 3.13-9.39)) while no association was observed among users with a group of other indications, including peptic ulcer and "gastroduodenal symptoms" (that is, gastritis, dyspepsia, indigestion, and epigastric pain) (OR 1.74 (95% CI 0.90-3.34)).
  • "Peptic ulcer" indication (that is, gastric ulcer, duodenal ulcer, or unspecified peptic ulcer) was associated with a greater than fourfold increased risk of gastric non-cardia adenocarcinoma among long term users (OR 4.66 (95% CI 2.42-8.97)) but no such association was found in those treated for a group of other indications (that is, "oesophageal" or "gastroduodenal symptoms") (OR 1.18 (95% CI 0.60-2.32)).
  • CONCLUSIONS: Long term pharmacological gastric acid suppression is a marker of increased risk of oesophageal and gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antacids / adverse effects. Esophageal Neoplasms / chemically induced. Stomach Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Ulcer Agents / administration & dosage. Anti-Ulcer Agents / adverse effects. Cardia. Drug Administration Schedule. Epidemiologic Methods. Great Britain / epidemiology. Histamine H2 Antagonists / administration & dosage. Histamine H2 Antagonists / adverse effects. Humans. Middle Aged. Proton Pump Inhibitors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Mar;24(3):315-20 [10658066.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):961-8 [17654746.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):661-9 [10734017.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Jun;14(6):651-68 [10848649.001]
  • [Cites] Eur J Cancer Prev. 2000 Jun;9(3):185-91 [10954258.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1286-93 [11729107.001]
  • [Cites] Digestion. 2001;64(4):205-13 [11842276.001]
  • [Cites] Pharmacol Toxicol. 2001 Dec;89(6):281-6 [11903952.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Am J Ther. 2002 May-Jun;9(3):199-205 [11941379.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):686-9 [12741446.001]
  • [Cites] Expert Opin Drug Saf. 2002 May;1(1):29-38 [12904157.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Lancet. 1979 May 12;1(8124):1005-6 [86721.001]
  • [Cites] Digestion. 1986;35 Suppl 1:42-55 [3792671.001]
  • [Cites] N Engl J Med. 1988 Jul 28;319(4):195-200 [3393171.001]
  • [Cites] Lancet. 1990 Aug 11;336(8711):355-7 [1975342.001]
  • [Cites] BMJ. 1991 Mar 30;302(6779):766-8 [2021768.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Nutrition. 1992 May-Jun;8(3):177-81 [1356031.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Q J Med. 1991 Jan;78(285):13-9 [1670060.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] N Engl J Med. 1996 Apr 18;334(16):1018-22 [8598839.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):242-9 [8657240.001]
  • [Cites] Epidemiology. 1996 Jul;7(4):434-6 [8793372.001]
  • [Cites] Gut. 1997 Feb;40(2):247-52 [9071940.001]
  • [Cites] Eur J Cancer Prev. 1997 Feb;6(1):20-3 [9161808.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [CommentIn] Gut. 2007 Jul;56(7):1023 [17566037.001]
  • [CommentIn] Gut. 2006 Nov;55(11):1532-3 [17047103.001]
  • (PMID = 16785284.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antacids; 0 / Anti-Ulcer Agents; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Other-IDs] NLM/ PMC1860118
  •  go-up   go-down


53. Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyrén O: The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis; 2006 Sep;27(9):1835-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden.
  • Mechanisms behind the strong associations of esophageal adenocarcinoma risk with gastroesophageal reflux (GOR) and body mass remain to be defined.
  • In a nationwide population-based case-control study, we examined associations of polymorphisms in the DNA repair genes XPD, XPC, XRCC1 and XRCC3 with risk of esophageal adenocarcinoma, squamous-cell carcinoma (SCC) and gastric cardia adenocarcinoma, and paid special attention to possible interactions with symptomatic reflux or body mass.
  • We collected blood samples from 96, 81 and 126 interviewed incident cases of esophageal adenocarcinoma, esophageal SCC and gastric cardia adenocarcinoma, respectively, and 472 randomly selected controls, frequency-matched with regard to age and sex.
  • XPD codon 751 Lys/Gln and Gln/Gln genotypes, compared with Lys/Lys genotype, were both associated with a more than doubled risk for esophageal adenocarcinoma (OR=2.4; 95% CI=1.4-4.4; OR=2.7, 95% CI=1.3-5.9).
  • Our study suggests that XPD 751Gln allele is a potential genetic marker for susceptibility to esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Xeroderma Pigmentosum Group D Protein / genetics. Xeroderma Pigmentosum Group D Protein / physiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / genetics. Case-Control Studies. Female. Humans. Male. Middle Aged. Polymorphism, Genetic. Risk. Stomach Neoplasms / genetics. Sweden

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571649.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA57947-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


54. Wang GQ, Wei WQ, Zhang JH: [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases]. Ai Zheng; 2007 Nov;26(11):1153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases].
  • BACKGROUND & OBJECTIVE: The survival time of untreated advanced gastric cardiac adenocarcinoma patients is about 8-9 months.
  • This study was to observe the natural progression of untreated early stage gastric cardiac adenocarcinoma.
  • METHODS: In 1987, at a high risk area of esophageal cancer, 851 patients with a previous cytologic diagnosis of esophageal dysplasia were re-examined by endoscopy, and 43 of them were diagnosed histologically as gastric cardiac adenocarcinoma.
  • RESULTS: Of the 17 untreated patients, 12 were died of gastric cardiac adenocarcinoma, 5 were died of non-cancer diseases; 13 had survived for over 5 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Disease Progression. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991310.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


55. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH: Intraoperative frozen section margin evaluation in gastric cancer of the cardia surgery. Hepatogastroenterology; 2006 Nov-Dec;53(72):976-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative frozen section margin evaluation in gastric cancer of the cardia surgery.
  • Our aim was to identify the value of intraoperative frozen section in margin evaluation and to investigate its indication for gastric cancer of the cardia.
  • METHODOLOGY: Intraoperative frozen section examinations of the proximal margins of 66 patients with gastric adenocarcinoma of the cardia were reviewed.
  • CONCLUSIONS: Routine evaluation of the proximal resection margin by intraoperative frozen section does not appear to be necessary in gastric cancer surgery of the cardia.
  • [MeSH-major] Cardia / pathology. Cardia / surgery. Frozen Sections / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17153467.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


56. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T: Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus; 2007;20(1):36-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?
  • Adenocarcinoma of the distal esophagus and gastroesophageal junction are believed to arise in Barrett's esophagus with intestinal metaplasia.
  • Whether adenocarcinoma can arise in columnar lined esophagus without intestinal metaplasia is in doubt.
  • Whether adenocarcinoma of the gastric cardia arises in intestinal metaplasia of the gastric cardia is also in doubt.
  • We aim to evaluate the relationship of size and stage of adenocarcinoma of the distal esophagus, gastroesophageal junction and gastric cardia to intestinal metaplasia and other types of columnar epithelium.
  • Residual intestinal metaplasia was present in 48 (65%) tumors, including 33/38 (87%) distal esophageal, 10/25 (45%) junctional and 5/11 (45%) gastric cardia tumors.
  • These data strongly support the contention that adenocarcinomas of this region, including those in the gastric cardia, arise in intestinal metaplastic epithelium.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227308.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Solerio D, Camandona M, Gasparri G, Casalegno PA, Raggio E, Dei Poli M: [The choice of surgical therapy in adenocarcinoma of the cardia]. Minerva Chir; 2005 Feb;60(1):17-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The choice of surgical therapy in adenocarcinoma of the cardia].
  • [Transliterated title] La scelta della terapia chirurgica nell'adenocarcinoma del cardias.
  • AIM: From 1996 the adenocarcinoma of the esophago-gastric junction (AEG) is divided into 3 types according to Siewert's classification.
  • METHODS: From 1990 to 2002 we have performed 111 resections for adenocarcinoma of the cardia: 25 for AEG type I (all esophago-gastric resection), 39 for type II (22 esophago-gastric resection, 17 extended total gastrectomy with esophageal resection) and 47 for type III (8 esophago-gastric resection, 39 extended total gastrectomy with esophageal resection).
  • CONCLUSIONS: According to the results of our study and those of the other authors, who have showed that a 10 cm distance of the neoplasm by the gastric side and the esophageal one could assure oncologic radicality and also that metastatic lymph nodes below pylorus and near greater curvature are uncommon, we can consider esophago-gastric resection for AEG II a speedy, safe and oncologically correct surgical treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902049.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Yoon HY, Kim HI, Kim CB: [Clinicopathologic characteristics of adenocarcinoma in cardia according to Siewert classification]. Korean J Gastroenterol; 2008 Nov;52(5):293-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of adenocarcinoma in cardia according to Siewert classification].
  • BACKGROUND/AIMS: The aim of this study was to evaluate clinicopathologic differences between Type II and Type III groups that were classified by Siewert in cardia cancer.
  • METHODS: A hundred forty-one patients who were diagnosed as gastric cardia cancer and underwent surgery between January 1990 and December 2006 by single surgeon at Department of Surgery, Yonsei University College of Medicine were included in this study.
  • RESULTS: Barrett's adenocarcinoma was recognized in two patients so called type I.
  • CONCLUSIONS: Several clinicopathologic differences exist between type II and III cardia cancer.
  • In the future, further evaluation is needed regarding the classification and entities of the cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077475.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


59. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D: Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis; 2007 Sep;28(9):1996-2001
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
  • This study examined the effect of P53 Arg72Pro variants on transactivation of polymorphic MDM2 promoter (T309G) and their associations with risk of developing gastric cardia adenocarcinoma (GCA) in a Chinese population.
  • [MeSH-major] Amino Acid Substitution. Polymorphism, Genetic. Polymorphism, Single Nucleotide. Proto-Oncogene Proteins c-mdm2 / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638920.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Tumor Suppressor Protein p53; 5Z93L87A1R / Guanine; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; QR26YLT7LT / Thymine
  •  go-up   go-down


60. Kubo A, Corley DA: Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):872-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis.
  • BACKGROUND: The incidence of esophageal adenocarcinoma has increased markedly in recent decades in many countries.
  • We did a systematic review and statistical synthesis of studies that evaluated the association between body mass index (BMI) and the risk of esophageal adenocarcinoma or the adjacent gastric cardia adenocarcinoma.
  • (b) the occurrence of esophageal or cardia adenocarcinoma diagnosis; and (c) a relative risk or odds ratio (OR) with confidence intervals (CI) or provided sufficient data to permit their calculation.
  • RESULTS: We identified 14 studies (2 cohort, 12 case-control; 2,488 esophageal and 2,509 cardia adenocarcinomas).
  • A high BMI (>25) was associated with an increased risk of esophageal adenocarcinoma (males, OR, 2.2; 95% CI, 1.7-2.7; females, OR, 2.0; 95% CI, 1.4-2.9).
  • The overall associations with cardia cancer were heterogeneous, although stratification by study location provided homogeneous results for populations from the United States or Europe.
  • A high BMI was weakly associated with the risk of cardia adenocarcinoma (OR, 1.5; 95% CI, 1.3-1.8; P(heterogeneity) = 0.38).
  • CONCLUSIONS: Pooled results from observational studies support a positive association between high BMI and the risk for esophageal and possibly for cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Body Mass Index. Esophageal Neoplasms / epidemiology. Obesity / complications. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Cardia. Female. Humans. Male. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702363.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08DK002697; United States / NIDDK NIH HHS / DK / R01 DK63616
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


61. Kanai M, Torii A, Hamada A, Endo Y, Takeda Y, Yamakawa M, Hikita H, Nishikawa H, Ochi J, Miura K, Noguchi M, Kashu I, Sakurai T: Pure gastric yolk sac tumor that was diagnosed after curative resection: case report and review of literature. Int J Gastrointest Cancer; 2005;35(1):77-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure gastric yolk sac tumor that was diagnosed after curative resection: case report and review of literature.
  • We recently experienced an 87-yr-old man with gastric yolk sac tumor.
  • Preoperative diagnosis was poorly differentiated adenocarcinoma in the cardia of stomach without apparent metastasis.
  • The precise histological examination after surgery revealed the tumor was composed of pure gastric yolk sac tumor without adenocarcinomatous components.
  • Gastric yolk sac tumors are very rare, and only six cases of gastric yolk sac tumors have been previously reported in the literature.
  • Five out of six cases are accompanied by components of adenocarcinoma, and our present case is the second report of pure gastric yolk sac tumor to the best of our knowledge.
  • [MeSH-major] Adenocarcinoma / surgery. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1976 Sep;7(5):595-604 [987011.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):927-8 [8375864.001]
  • [Cites] Cancer. 1999 May 1;85(9):1910-6 [10223229.001]
  • [Cites] J Clin Gastroenterol. 2000 Jul;31(1):85-8 [10914786.001]
  • [Cites] Acta Pathol Jpn. 1985 Mar;35(2):497-505 [2411108.001]
  • [Cites] Hum Pathol. 1985 Sep;16(9):955-8 [4040885.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):557-62 [10469400.001]
  • (PMID = 15722577.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: Comparison of transthoracic and transabdominal surgical approaches for the treatment of adenocarcinoma of the cardia. Chin J Cancer; 2010 Aug;29(8):747-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of transthoracic and transabdominal surgical approaches for the treatment of adenocarcinoma of the cardia.
  • BACKGROUND AND OBJECTIVE: Transthoracic and transabdominal approaches are commonly used for the surgical treatment of adenocarcinoma of the cardia.
  • Our study aimed to compare the surgical trauma, range of lymph node dissection, and the prognosis of the transthoracic and transabdominal approaches for the treatment of adenocarcinoma of the cardia.
  • METHODS: The medical records of 331 patients with adenocarcinoma of the cardia treated in our hospital between 1994 and 2003 were analyzed.
  • CONCLUSIONS: For the surgical treatment of adenocarcinoma of the cardia, the surgical trauma of the transthoracic approach is similar with that of transabdominal approach.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia / surgery. Gastrectomy / methods. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663322.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Navarro Silvera SA, Mayne ST, Risch H, Gammon MD, Vaughan TL, Chow WH, Dubrow R, Schoenberg JB, Stanford JL, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr: Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer; 2008 Aug 15;123(4):852-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Food group intake and risk of subtypes of esophageal and gastric cancer.
  • Incidence rates for adenocarcinomas of the esophagus and gastric cardia have been increasing rapidly, while rates for non-cardia gastric adenocarcinoma and esophageal squamous cell carcinoma have declined.
  • We examined food group intake as a risk factor for subtypes of esophageal and gastric cancers in a multicenter, population-based case-control study in Connecticut, New Jersey and western Washington state.
  • Total vegetable intake was associated with decreased risk of esophageal adenocarcinoma (OR = 0.85, 95% CI = 0.75, 0.96).
  • Conversely, total meat intake was associated with increased risk of esophageal adenocarcinoma (OR = 1.43, 95% CI = 1.11, 1.83), gastric cardia adenocarcinoma (OR = 1.37, 95% CI = 1.08, 1.73) and noncardia gastric adenocarcinoma (OR = 1.39, 95% CI = 1.12, 1.71), with red meat most strongly associated with esophageal adenocarcinoma risk (OR = 2.49, 95% CI = 1.39, 4.46).
  • Poultry was most strongly associated with gastric cardia adenocarcinoma (OR = 1.89, 95% CI = 1.15, 3.11) and noncardia gastric adenocarcinoma (OR = 1.90, 95% CI = 1.19, 3.03).
  • High-fat dairy was associated with increased risk of both esophageal and gastric cardia adenocarcinoma.
  • Higher intake of meats, particularly red meats, and lower intake of vegetables were associated with an increased risk of esophageal adenocarcinoma, while higher intake of meats, particularly poultry, and high-fat dairy was associated with increased risk of gastric cardia adenocarcinoma.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Int J Epidemiol. 1991 Mar;20(1):39-44 [2066242.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):240-52 [8740737.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):14-9 [9096659.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1247-9 [9293909.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Am J Epidemiol. 1997 Nov 15;146(10):856-69 [9384206.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):7-12 [9533754.001]
  • [Cites] Int J Cancer. 1998 Nov 9;78(4):415-20 [9797127.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Cancer Causes Control. 1991 Nov;2(6):427-42 [1764568.001]
  • [Cites] Lancet. 1992 May 30;339(8805):1314-8 [1349991.001]
  • [Cites] Am J Epidemiol. 1992 Jul 15;136(2):178-91 [1415140.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):38-46 [8150539.001]
  • [Cites] Int J Cancer. 1994 Jul 15;58(2):197-202 [8026881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):387-92 [7920205.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):289-94 [10861489.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Eur J Cancer Prev. 2000 Aug;9(4):257-63 [10958328.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):387-91 [11159879.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):163-72 [11246845.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Clin Nutr. 2002 Jan;75(1):137-44 [11756071.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):852-6 [10074917.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):17-21 [10211305.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):33-7 [10360817.001]
  • [Cites] Nutr Cancer. 2001;40(2):103-7 [11962244.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):37-42 [12085253.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):940-4 [14504209.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1209-14 [14520448.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12045-50 [14523234.001]
  • [Cites] Science. 1972 Jul 7;177(4043):65-8 [5041776.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Ann N Y Acad Sci. 1975 Sep 30;258:181-9 [1060401.001]
  • [Cites] J Natl Cancer Inst. 1981 Dec;67(6):1199-206 [6947105.001]
  • [Cites] Nutr Cancer. 1987;9(2-3):81-92 [3562297.001]
  • [Cites] Nutr Cancer. 1987;10(1-2):103-13 [3112746.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3843-8 [3378219.001]
  • [Cites] J Natl Cancer Inst. 1988 Oct 5;80(15):1237-43 [3418729.001]
  • [Cites] J Natl Cancer Inst. 1988 Dec 21;80(20):1620-5 [3193480.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4497-500 [2369728.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):350-4 [2040528.001]
  • (PMID = 18537156.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01-CA57923; United States / NCI NIH HHS / CA / U01-CA57983; United States / NCI NIH HHS / CN / N01-CN05230; United States / NCI NIH HHS / CA / U01-CA57949; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CP / N02-CP40501; United States / Intramural NIH HHS / / Z01 CP010136-12
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS256966; NLM/ PMC3008621
  •  go-up   go-down


64. Kim MA, Lee HS, Yang HK, Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer; 2005 Apr 1;103(7):1439-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach.
  • BACKGROUND: Although the incidence of adenocarcinoma of the stomach has decreased over the past several decades, gastric cardia carcinoma has increased over the same period.
  • METHODS: The clinicopathologic characteristics and immunohistochemical staining results of 21 proteins were investigated in 165 patients with cardia carcinoma, including 74 patients with true cardia carcinoma and 91 patients with subcardia carcinoma, and the results were compared with the results from 564 patients with noncardia carcinoma.
  • RESULTS: In the clinicopathologic analysis, patients who had cardia carcinoma tended to have tumors with poorly differentiated histology according to the World Health Organization classification system (P = 0.012), diffuse type according to the Lauren classification system (P = 0.049), and advanced pathologic TNM stage (P < 0.001).
  • On immunohistochemical staining, loss of the p16 (P = 0.038) and smad4 (P < 0.001) tumor suppressor genes was more frequent in cardia carcinoma than in noncardia carcinoma.
  • Carcinoembryonic antigen and CD44 overexpression were more frequent in patients with cardia carcinoma (P < 0.05).
  • Conversely, patients who had cardia carcinoma exhibited less frequent expression of MUC1 (P = 0.008) and MUC5AC (P = 0.006) compared with patients who had noncardia carcinoma.
  • Epstein-Barr virus infection was more common in patients with cardia carcinoma (P < 0.001).
  • In the survival analysis, the patients with cardia carcinoma had a poorer prognosis.
  • In the multivariate analysis, tumor location in the cardia was confirmed as an independent, poor prognostic factor in patients with gastric carcinoma.
  • CONCLUSION: Cardia carcinoma and noncardia carcinoma differed in their clinicopathologic characteristics and in their alterations of gene expression, as evaluated by immunohistochemistry.
  • The current results support the hypothesis that cardia carcinoma forms a specific category of gastric carcinoma that is distinct from noncardia carcinoma.
  • [MeSH-major] Carcinoma / pathology. Cardia. Gene Expression Profiling. Stomach Neoplasms / pathology


65. Vial M, Grande L, Pera M: Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:1-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • The incidence of adenocarcinoma of the esophagus and esophagogastric junction (gastric cardia) has risen rapidly over the past three decades in the United States and northern Europe.
  • However, less than 10% of the patients with esophageal adenocarcinoma were known to have Barrett's esophagus before.
  • Current evidence indicates that gastroesophageal reflux and obesity are major risk factors for adenocarcinoma of the esophagus.
  • Abdominal obesity, more prevalent in males, and independent of body mass index, seems to be associated with an increased risk of esophageal adenocarcinoma but not of cardia adenocarcinoma.
  • This observation may explain the high male:female ratio observed in esophageal adenocarcinoma.
  • Tobacco use has also been found as a possible risk factor for adenocarcinoma of the esophagus and gastric cardia.
  • On the other hand, low intake of fruits, vegetables, and cereal fibers seem to increase the risk of esophageal adenocarcinoma.
  • Currently, there is no evidence that strongly supports any specific strategy to screen a subgroup of the population at risk for adenocarcinoma of the esophagus or esophagogastric junction.
  • Future strategies to decrease obesity and tobacco use might help to reduce the burden of esophageal adenocarcinoma at least partially.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676867.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


66. Chak A, Faulx A, Eng C, Grady W, Kinnard M, Ochs-Balcom H, Falk G: Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer; 2006 Nov 1;107(9):2160-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia.
  • BACKGROUND: The efficacy of endoscopic screening for chronic gastroesophageal reflux symptoms of heartburn and regurgitation in adult subjects depends on the sensitivity of this strategy for detecting Barrett esophagus in subjects before the development of adenocarcinoma of the esophagus or cardia.
  • The aim of the current study was to determine what proportion of patients with cancer of the esophagus or cardia would have been candidates for a screening endoscopy before their cancer diagnosis based on the presence and duration of preceding reflux symptoms.
  • METHODS: All patients with adenocarcinoma of the esophagus, adenocarcinoma of the cardia, or long-segment Barrett esophagus presenting for endoscopy at 4 tertiary care and 2 Veterans Affairs (VA) hospitals were given a previously validated questionnaire to determine their recall of common gastroesophageal reflux symptoms.
  • Only 67 of 110 patients (61%) with adenocarcinoma of the esophagus and 8 of 21 patients (38%) with adenocarcinoma of the cardia recalled symptoms of heartburn or regurgitation being present for >5 years before their diagnosis of cancer.
  • Only 40 of 110 patients (36%) with adenocarcinoma of the esophagus and 5 of 21 patients (24%) with adenocarcinoma of the cardia recalled weekly symptoms being present for >5 years before their cancer diagnosis.
  • CONCLUSIONS: Current practice, which uses a screening strategy of performing endoscopy in patients with >5 years of heartburn or regurgitation, can detect Barrett epithelium in only a limited proportion of those patients at risk for developing adenocarcinoma of the esophagus or adenocarcinoma of the cardia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Cardia / pathology. Esophageal Neoplasms / diagnosis. Gastroesophageal Reflux / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17019737.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK002800; United States / NIDDK NIH HHS / DK / DK061426; United States / NIDDK NIH HHS / DK / DK070863
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Lehmann K, Schneider PM: Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:65-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Adenocarcinoma of the distal esophagus, gastric cardia, and upper gastric third are grouped in type I-III by the Siewert classification.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676871.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


68. Rubenstein JH, Davis J, Marrero JA, Inadomi JM: Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther; 2005 Aug 1;22(3):267-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia.
  • BACKGROUND: Obesity is a risk factor for adenocarcinomas of the oesophagus and gastric cardia.
  • AIM: To estimate the risk of diabetes mellitus on the development of adenocarcinoma of distal oesophagus and gastric cardia beyond that of gastro-oesophageal reflux disease.
  • CONCLUSIONS: Within the limitations of this case-control study, there is no evidence of an association between diabetes and adenocarcinoma of the oesophagus or gastric cardia among US veterans with gastro-oesophageal reflux disease.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Diabetes Mellitus. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091065.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA864000; United States / NIDDK NIH HHS / DK / DK064909
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


69. Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB: Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology; 2005 May-Jun;52(63):944-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer.
  • BACKGROUND/AIMS: Abnormal function of gene p53 is associated with the formation of various cancers including gastric cancer.
  • In this study, we evaluated the risk factors associated with p53 codon 72 polymorphism and gastric cancer carcinogenesis.
  • The proline homozygote was more frequent in the patients with gastric cancer at the cardia than in those with cancer at the antral or corpus locations. (55.56% of cardia vs. 14.28% of corpus and antrum, p=0.024).
  • The arginine allele was associated with antral and corpus location of gastric cancer and the proline allele was associated with cardial location (OR=3.25, p=0.026).
  • CONCLUSIONS: The proline allele at p53 codon 72 is associated with adenocarcinoma of the gastric cardia, and the arginine allele is associated with cancer of the antral and corpus locations.
  • These findings suggest that different genotypes of the p53 gene in different locations of stomach might implicate a different cause of tumor growth.
  • [MeSH-major] Alleles. Arginine / genetics. Cardia. Codon. Gastric Fundus. Genes, p53 / genetics. Polymorphism, Single Nucleotide. Proline / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966238.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


70. Yu GZ, Chen Y, Wang JJ: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol; 2009 Oct;135(10):1331-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.
  • PURPOSE: Growth factor receptor-bound 2 (Grb2)-mediated HER2 signaling is thought to play a critical role in gastric cancer development, progression and metastasis.
  • However, little is known about their expression in gastric cancer.
  • In this study, we try to explore their relationship with clinicopathological parameters and prognostic significance in gastric cancer patients.
  • MATERIALS AND METHODS: We examined the expression of Grb2 and HER2 in normal gastric mucosa, primary gastric cancers, and lymph node metastases using immunohistochemical analysis of tissue microarrays containing specimens obtained from 1,143 patients with gastric cancer.
  • Overexpression of Grb2 and Her2 was associated with age (>60 years), tumor location (cardia of stomach), adenocarcinoma, and high/moderate differentiation.
  • CONCLUSIONS: Our data demonstrated a progressive amplification of Grb2 and HER2 expression in gastric carcinogenesis, suggesting the importance of Grb2 and HER2 as positive biomarkers for gastric cancer development and progression.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. GRB2 Adaptor Protein / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Oct;183(2):195-203 [9390033.001]
  • [Cites] Cell. 1992 Aug 7;70(3):431-42 [1322798.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):171-93 [15892618.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6311-8 [14508511.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23 (4):304-9 [9315057.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):363-8 [11054664.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):290-4 [16376541.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Int J Surg Pathol. 2002 Oct;10(4):247-56 [12490974.001]
  • [Cites] J Surg Oncol. 1992 Apr;49(4):209-12 [1348293.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):238-45 [16341149.001]
  • [Cites] Neuron. 1992 Sep;9(3):383-91 [1326293.001]
  • [Cites] Surgery. 1994 Mar;115(3):349-54 [7907434.001]
  • [Cites] Cell. 1991 Jan 25;64(2):281-302 [1846320.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):540-8 [14696118.001]
  • [Cites] Oncogene. 1994 Dec;9(12):3601-8 [7970720.001]
  • [Cites] Int J Biol Markers. 2004 Oct-Dec;19(4):268-74 [15646832.001]
  • [Cites] Histopathology. 1998 Apr;32(4):335-9 [9602330.001]
  • [Cites] J Med Chem. 1999 Jan 14;42(1):25-35 [9888830.001]
  • [Cites] Chin Med Sci J. 1997 Jun;12(2):67-70 [11324501.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2914-8 [1673870.001]
  • [Cites] Int J Biol Markers. 2001 Oct-Dec;16(4):250-4 [11820720.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):371-8 [8570214.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):13-20 [16317285.001]
  • [Cites] Cell. 1998 Dec 11;95(6):793-803 [9865697.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):437-43 [15672868.001]
  • [Cites] FEBS Lett. 1994 Jan 31;338(2):113-7 [8307166.001]
  • [Cites] Diagn Mol Pathol. 2001 Sep;10(3):139-52 [11552716.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1191-204 [18425376.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):65-71 [16328035.001]
  • [Cites] FEBS Lett. 1995 Aug 1;369(1):47-51 [7641883.001]
  • [Cites] Oncology. 1995 Sep-Oct;52(5):385-91 [7637956.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1504-13 [17088902.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):308-14 [17419281.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1800-11 [11896612.001]
  • [Cites] Oncogene. 2007 Oct 4;26(45):6469-87 [17471238.001]
  • [Cites] Pathol Oncol Res. 2002;8(4):252-6 [12579211.001]
  • (PMID = 19337752.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


71. Wachowiak R, Kaifi JT, Schurr PG, Merkert P, Yekebas E, Schwarzenbach H, Strate T, Sauter G, Izbicki JR: Similar patterns of loss of heterozygosity in serum of adenocarcinoma of the distal oesophagus and the cardia in early diagnosis. Anticancer Res; 2007 Jan-Feb;27(1A):477-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar patterns of loss of heterozygosity in serum of adenocarcinoma of the distal oesophagus and the cardia in early diagnosis.
  • The aim of our study was to investigate LOH in the serum of patients with adenocarcinoma of the distal oesophagus and the cardia for diagnostic and prognostic utility.
  • PATIENTS AND METHODS: Matched tumour and serum samples from 46 surgically treated patients with oesophageal adenocarcinoma and cardia carcinoma divided in two groups were analysed.
  • CONCLUSION: The results indicate that DNA alterations in tumours of the oesophagus and cardia are uniform.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia. Esophageal Neoplasms / genetics. Loss of Heterozygosity. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352270.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


72. Schmassmann A, Oldendorf MG, Gebbers JO: Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007. Eur J Epidemiol; 2009;24(10):603-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007.
  • Several Western countries have reported a decrease in the incidence of noncardia gastric adenocarcinoma and a strong increase in the incidence of oesophageal and cardia adenocarcinoma.
  • We examined incidence rates of gastric and oesophageal cancer by subsite and histology in Central Switzerland over the last 26 years.
  • Data on biopsy-diagnosed gastric and oesophageal carcinoma incidence during 1982-2007 were obtained from the Cancer Registry of the Institute of Pathology, Lucerne, the Medical Centre for Central Switzerland.
  • In total, 2,322 cancers were diagnosed: 1,240 noncardia gastric adenocarcinomas, 459 cardia gastric adenocarcinomas, 248 oesophageal adenocarcinomas, and 375 squamous cell carcinomas.
  • From 1982 to 2007, the incidence rates of noncardia adenocarcinoma decreased substantially from 17.9 (per 100,000) to 6.0 in men and 10.3 to 5.5 in women.
  • In men, the incidence of gastric cardia adenocarcinoma decreased from 7.5 to 4.3, the incidence of oesophageal adenocarcinoma increased from 3.3 to 4.8, and the incidence of oesophageal squamous cell carcinoma decreased from 6.6 to 4.1; the incidence rates of these cancers were low in women (1.1-2.4).
  • In conclusion, the incidence of gastric noncardia carcinoma has decreased substantially over the past 26 years.
  • In contrast to other Western countries, the incidence of gastric cardia adenocarcinoma did not increase in Central Switzerland.
  • Whereas the rate of oesophageal adenocarcinoma increased, the rate of squamous cell carcinoma decreased.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cardia / pathology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Eur J Surg. 2001 Oct;167(10):748-57 [11775726.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Nat Med. 2000 Apr;6(4):376-7 [10742137.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1167-71 [1627389.001]
  • [Cites] Eur J Cancer Prev. 1992 Feb;1(2):159-64 [1463978.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Apr;13(4):356-62 [9641297.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):374-7 [8472157.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Swiss Med Wkly. 2003 Sep 26;133(37-38):507-14 [14652799.001]
  • [Cites] Aust N Z J Surg. 1996 May;66(5):271-5 [8634040.001]
  • [Cites] Praxis (Bern 1994). 2005 May 25;94(21):861-8 [15966485.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):330-40 [8319166.001]
  • [Cites] Int J Cancer. 1998 Jan 5;75(1):160-1 [9426706.001]
  • [Cites] Int J Epidemiol. 1994 Apr;23(2):246-51 [8082949.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):747-9 [10328099.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):858-64 [2010228.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):761-8 [8896886.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):271-4 [1467773.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):387-90 [10917556.001]
  • [Cites] Eur J Cancer Prev. 1999 Dec;8(6):479-86 [10643936.001]
  • (PMID = 19669623.001).
  • [ISSN] 1573-7284
  • [Journal-full-title] European journal of epidemiology
  • [ISO-abbreviation] Eur. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Jansson C, Plato N, Johansson AL, Nyrén O, Lagergren J: Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma. Occup Environ Med; 2006 Feb;63(2):107-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma.
  • BACKGROUND: The reasons for the increasing incidence of and strong male predominance in patients with oesophageal and cardia adenocarcinoma remain unclear.
  • METHODS: In a nationwide Swedish population based case control study, 189 and 262 cases of oesophageal and cardia adenocarcinoma respectively, 167 cases of oesophageal squamous cell carcinoma, and 820 frequency matched controls underwent personal interviews.
  • RESULTS: Tendencies of positive associations were found between high exposure to pesticides and risk of oesophageal (OR 2.3 (95% CI 0.9 to 5.7)) and cardia adenocarcinoma (OR 2.1 (95% CI 1.0 to 4.6)).
  • There was a twofold increased risk of oesophageal squamous cell carcinoma among concrete and construction workers (OR 2.2 (95% CI 1.1 to 4.2)) and a nearly fourfold increased risk of cardia adenocarcinoma among workers within the motor vehicle industry (OR 3.9 (95% CI 1.5 to 10.4)).
  • An increased risk of oesophageal squamous cell carcinoma (OR 3.9 (95% CI 1.2 to 12.5)), and a tendency of an increased risk of cardia adenocarcinoma (OR 2.8 (95% CI 0.9 to 8.5)), were identified among hotel and restaurant workers.
  • CONCLUSIONS: Specific airborne occupational exposures do not seem to be of major importance in the aetiology of oesophageal or cardia adenocarcinoma and are unlikely to contribute to the increasing incidence or the male predominance.
  • [MeSH-major] Air Pollutants, Occupational / toxicity. Cardia. Esophageal Neoplasms / etiology. Occupational Diseases / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Epidemiologic Methods. Female. Humans. Industry. Inhalation Exposure / adverse effects. Inhalation Exposure / analysis. Male. Middle Aged. Occupational Exposure / adverse effects. Occupational Exposure / analysis. Occupations. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 2005 Apr;15(4):279-85 [15780775.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Dig Dis Sci. 2002 Mar;47(3):568-72 [11911344.001]
  • [Cites] Am J Ind Med. 2002 Jul;42(1):11-22 [12111686.001]
  • [Cites] Am J Ind Med. 2003 May;43(5):519-22 [12704624.001]
  • [Cites] Environ Res. 2003 Nov;93(3):264-71 [14615236.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Am J Ind Med. 2004 Aug;46(2):161-9 [15273969.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] Occup Environ Med. 2004 Sep;61(9):743-9 [15317914.001]
  • [Cites] Eur J Epidemiol. 2004;19(7):631-41 [15461194.001]
  • [Cites] Eur J Epidemiol. 2004;19(7):643-50 [15461195.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] Am J Ind Med. 1997 Mar;31(3):280-6 [9055950.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] Am J Ind Med. 1999 Mar;35(3):272-80 [9987560.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Surg Oncol. 2001 Nov;10(3):81-90 [11750227.001]
  • (PMID = 16421388.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational
  • [Other-IDs] NLM/ PMC2078064
  •  go-up   go-down


74. Shen H, Newmann AS, Hu Z, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wang X, Wei Q: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep; 2005 Feb;13(2):355-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China.
  • Studies have suggested that low dietary folate intake is associated with an increased risk of gastric cancer.
  • C677T, A1298C and G1793A) and their haplotypes are associated with the risk of gastric cancer.
  • To test this hypothesis, we genotyped these polymorphisms in a population-based case-control study of 320 incident gastric adenocarcinoma cases and 313 cancer-free controls in a Chinese population.
  • Consistent with our previous observations, the 677TT genotype was associated with a significantly increased risk for gastric cancer (adjusted OR =1.79, 95% CI =1.02-3.15) compared with the 677CC genotype; the association was more evident for gastric cardia adenocarcinoma (adjusted OR =2.60, 95% CI =1.30-5.21).
  • When we used the haplotype analyses and assumed MTHFR 677T, 1298C and 1793A as risk alleles, individuals with 6 variant alleles had a significantly (4.64-fold) increased risk for gastric cardia adenocarcinoma (OR =4.64, 95% CI =1.34-16.01) compared with those having 0-2 variants.
  • These findings suggest that the MTHFR common variants and their haplotypes may play a role in the etiology of gastric cancer, particularly gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Asian Continental Ancestry Group / genetics. Cardia. Case-Control Studies. China / epidemiology. Female. Gene Frequency. Genetic Predisposition to Disease. Haplotypes. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643524.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


75. Jeon J, Luebeck EG, Moolgavkar SH: Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control; 2006 Sep;17(7):971-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States).
  • A number of hypotheses have been advanced to explain the rapid increase of the incidence of esophageal adenocarcinoma in the US.
  • To address this problem, we have developed multi-stage carcinogenesis models that describe the age-specific incidence of adenocarcinoma of the esophagus and of the gastric cardia with separate adjustments for temporal trends.
  • We fit these models separately to the incidence of adenocarcinoma of the esophagus and of the gastric cardia reported in the Surveillance Epidemiology and End Results (SEER) registry over the period 1973-2000.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841264.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047658; United States / NCI NIH HHS / CA / R01 CA119224-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


76. Bibeau F, Azria D, Chateau MC, Borrelly C, Ychou M, Quenet F, Rouanet P: [Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma]. Gastroenterol Clin Biol; 2006 Apr;30(4):611-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
  • [Transliterated title] Altérations vasculaires hépatiques après traitement néoadjuvant d'un adénocarcinome du cardia.
  • We report a case of a locally advanced cardial adenocarcinoma, occurring in a 48-year-old woman, who underwent concomitant radiotherapy and 5 FU-cis-platin based chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardia. Hepatic Veno-Occlusive Disease / etiology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733388.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Mal F, Perniceni T, Levard H, Denet C, Validire P, Gayet B: Pre-operative predictive factors of early recurrence after resection of adenocarcinoma of the esophagus and cardia. Gastroenterol Clin Biol; 2005 Dec;29(12):1275-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative predictive factors of early recurrence after resection of adenocarcinoma of the esophagus and cardia.
  • OBJECTIVES: To determine pre-operative predictive factors of early recurrence in patients with esophageal and cardial adenocarcinoma.
  • PATIENTS AND METHODS: We retrospectively analyzed consecutive patients who underwent resection for esophageal and cardial adenocarcinoma in our institution between October 1992 and October 2001.
  • Tumor was located in lower esophagus in 71 cases and at the cardia in 29 cases.
  • CONCLUSION: Important weight loss could be a pre-operative predictive factor of early recurrence after resection of esophageal and cardial adenocarcinoma and surgery as first line treatment could be avoided in these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia / surgery. Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518287.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


78. McColl KE: Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol; 2006;20(4):687-96
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the gastric cardia.
  • Current evidence indicates that cardia cancers are of at least two distinct and disparate aetiologies.
  • One type resembles cancer of the more distal stomach (Type A), being a consequence of atrophic gastritis due to Helicobacter pylori infection or more rarely autoimmune atrophic gastritis.
  • Another type (Type B) resembles oesophageal adenocarcinoma and is likely to be a consequence of short-segment gastro-oesophageal reflux disease.
  • The two cancers are themselves indistinguishable but examination of the gastric phenotype indicates the aetiology: Type A occurring in patients with evidence of atrophic gastritis whereas Type B occurs in subjects with healthy acid secreting stomachs.
  • In subjects with healthy acid secreting stomachs the cardia has a specific luminal chemistry remaining highly acidic and unbuffered following a meal and having very active nitrosative chemistry due to the acidification of nitrite in saliva.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997153.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


79. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ: Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol; 2005 Jul;58(7):722-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
  • BACKGROUND: It is sometimes difficult to distinguish between cardia cancer and oesophageal cancer.
  • METHODS: Consecutive patients with a malignant tumour in the oesophagus or stomach were recruited.
  • RESULTS: Endoscopically located adenocarcinoma of the oesophagus was present in 84 patients (64 men, 20 women; mean age, 68 years; range, 44-91).
  • Cancer located primarily in the gastric cardia was present in 63 patients (42 men, 21 women; mean age, 68 years; range, 42-88).
  • The histological diagnosis was metastasis from a primary tumour outside the oesophagus or stomach in 19 patients.
  • Patients in group A had definite oesophageal cancer, group B patients had a definite carcinoma located in the gastric cardia, and group C patients had an obstructing tumour distal in the oesophagus at the level of the diaphragm, which could not be passed with the endoscope.
  • CONCLUSION: CK phenotyping cannot distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cardia. Esophageal Neoplasms / diagnosis. Keratins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):445-54 [11962749.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Neth J Med. 2003 Jan;61(1):14-8 [12688564.001]
  • [Cites] Histopathology. 2003 Aug;43(2):127-34 [12877727.001]
  • [Cites] Pathol Res Pract. 2003;199(9):581-7 [14621193.001]
  • [Cites] Histopathology. 2003 Nov;43(5):453-61 [14636271.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):371-6 [15017595.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):487-94 [9309399.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):820-31 [11857318.001]
  • (PMID = 15976339.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770716
  •  go-up   go-down


80. Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, Liu B, Fan JH, Abnet CC: Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut; 2009 May;58(5):636-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.
  • OBJECTIVE: Low serum pepsinogen I (PGI) and low pepsinogen I/pepsinogen II ratio (PGI/II ratio) are markers of gastric fundic atrophy.
  • We aimed to prospectively test the association between serum PGI/II ratio and risks of gastric non-cardia adenocarcinoma, gastric cardia adenocarcinoma, and oesophageal squamous cell carcinoma (OSCC).
  • RESULTS: Compared to subjects with PGI/II ratio of >4, those with <or=4 had hazard ratios (HRs) (95% CIs) of 2.72 (1.77 to 4.20) and 2.12 (1.42 to 3.16) for non-cardia and cardia gastric adenocarcinomas, respectively.
  • The nonlinear continuous models suggested that any single cut point collapsed subjects with dissimilar gastric adenocarcinoma risks, and that using cut points was not an efficient use of data in evaluating these associations.
  • CONCLUSION: In this prospective study, we found similar and significantly increased risks of non-cardia and cardia gastric adenocarcinomas in subjects with low PGI/II ratio but little evidence for an association with the risk of OSCC.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Mar10;109(1):138-43 [14735480.001]
  • [Cites] Jpn J Cancer Res. 1995 Jan;86(1):64-71 [7737912.001]
  • [Cites] J Med Screen. 2004;11(3):141-7 [15333273.001]
  • [Cites] Gastroenterology. 1972 Oct;63(4):584-92 [5077145.001]
  • [Cites] Gastroenterology. 1982 Jul;83(1 Pt 2):204-9 [7084603.001]
  • [Cites] Clin Chim Acta. 1987 Mar 16;163(2):191-8 [3568423.001]
  • [Cites] Clin Invest Med. 1987 May;10(3):215-21 [3113799.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):113-7 [8467245.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] J Clin Gastroenterol. 1993 Jul;17(1):84 [8409305.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):461-6 [8220091.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] Int J Cancer. 2009 May 1;124(9):2135-8 [19107937.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1383-7 [9246033.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1032-6 [15742409.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):463-9 [15688378.001]
  • [Cites] Gut. 2005 Jun;54(6):764-8 [15888780.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2075-81 [15897993.001]
  • [Cites] Am J Epidemiol. 2006 Apr 1;163(7):629-37 [16443800.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1083-94 [16775164.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] Gut. 2007 Apr;56(4):457-9 [17369378.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1603-9 [17488251.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Jpn J Clin Oncol. 2008 Apr;38(4):259-67 [18344316.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):874-81 [18484586.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):456-60 [18844222.001]
  • [Cites] BMC Med Res Methodol. 2002;2:4 [11914137.001]
  • [Cites] Gut. 2002 Sep;51(3):457-8 [12171977.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):107-12 [11219766.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • (PMID = 19136509.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / N01-RC-47702; United States / NCI NIH HHS / SC / N01-SC-91030; United States / CCR NIH HHS / RC / N01RC47701; United States / CCR NIH HHS / RC / N01RC47702; United States / Intramural NIH HHS / / ZIA CP000112-05; United States / CCR NIH HHS / RC / N01-RC-47701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 61536-72-9 / Pepsinogen C; 9001-10-9 / Pepsinogen A
  • [Other-IDs] NLM/ NIHMS159682; NLM/ PMC2792746
  •  go-up   go-down


81. Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT: Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol; 2009 Nov 21;15(43):5465-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection.
  • RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups.
  • CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Carcinoma, Squamous Cell / microbiology. Cardia / microbiology. Esophageal Neoplasms / microbiology. Helicobacter Infections / blood. Helicobacter Infections / complications. Helicobacter pylori / immunology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2008 Oct;38(10):760-5 [18837801.001]
  • [Cites] Gut. 2008 Jun;57(6):727-33 [17895354.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):658-60 [11531247.001]
  • [Cites] J Gastroenterol. 2002;37 Suppl 13:28-33 [12109662.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):68-76 [12559187.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):123-8 [12593607.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):129-34 [12593608.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1202-4 [14520446.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;212:13-8 [8578226.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1442-7 [9136820.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1316-21 [9260797.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1271-6 [9707050.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):621-4 [10428200.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):588-93 [15743356.001]
  • [Cites] Helicobacter. 2005 Aug;10(4):312-7 [16104947.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1999-2000 [16708392.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2827-31 [17036331.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1188-99 [17383866.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):933-40 [17613922.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • (PMID = 19916178.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2778104
  •  go-up   go-down


82. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, Schatzkin A: A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol; 2007 Jun 15;165(12):1424-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes.
  • Rates of esophageal adenocarcinoma and gastric cardia adenocarcinoma have increased, while rates of esophageal squamous cell carcinoma (ESCC) and gastric noncardia adenocarcinoma have decreased, suggesting distinct etiologies.
  • Between 1995/1996 and 2000, 97 incident cases of ESCC, 205 of esophageal adenocarcinoma, 188 of gastric cardia, and 187 of gastric noncardia cancer occurred.
  • Compared with nonsmokers, current smokers were at increased risk for ESCC (hazard ratio (HR) = 9.27, 95% confidence interval (CI): 4.04, 21.29), esophageal adenocarcinoma (HR = 3.70, 95% CI: 2.20, 6.22), gastric cardia (HR = 2.86, 95% CI: 1.73, 4.70), and gastric noncardia (HR = 2.04, 95% CI: 1.32, 3.16).
  • Assuming causality, ever smoking had population attributable risks of 77% (95% CI: 0.55, 0.89) for ESCC, 58% (95% CI: 0.38, 0.72) for esophageal adenocarcinoma, 47% (95% CI: 0.27, 0.63) for gastric cardia, and 19% (95% CI: 0.00, 0.37) for gastric noncardia.
  • For drinkers of more than three alcoholic beverages per day, compared with those whose intake was up to one drink per day, the authors found significant associations between alcohol intake and ESCC risk (HR = 4.93, 95% CI: 2.69, 9.03) but not risk for esophageal, gastric cardia, or gastric noncardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Alcohol Drinking / adverse effects. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Smoking / adverse effects. Stomach Neoplasms / etiology


83. Alvarez Herrero L, Pouw RE, van Vilsteren FG, ten Kate FJ, Visser M, van Berge Henegouwen MI, Weusten BL, Bergman JJ: Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy; 2010 Dec;42(12):1030-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens.
  • BACKGROUND: Most risk estimations for lymph node metastasis in adenocarcinoma of the esophagus and cardia (AEC) with invasion into the muscularis mucosae (m3) or submucosa are based on surgical series.
  • [MeSH-major] Adenocarcinoma / secondary. Cardia / pathology. Esophageal Neoplasms / pathology. Mucous Membrane / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20960392.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


84. Reynolds JV, Murphy TJ, Ravi N: Multimodality therapy for adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:155-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality therapy for adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • There is considerable controversy over the level of recommendations from randomized trials underpinning management decisions for patients presenting with localized adenocarcinoma of the esophagus and esophagogastric junction.
  • [MeSH-major] Adenocarcinoma / therapy. Cardia. Esophageal Neoplasms / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676879.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


85. Lu CC, De-Chuan C, Lee HS, Chu HC: Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases. Am J Surg; 2010 Apr;199(4):e42-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases.
  • The authors report a rare case of hepatoid adenocarcinoma of the stomach, presenting initially with spleen and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cardia. Liver Neoplasms / diagnosis. Lymph Nodes / pathology. Splenic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359564.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


86. von Rahden BH, Feith M, Stein HJ: Carcinoma of the cardia: classification as esophageal or gastric cancer? Int J Colorectal Dis; 2005 Mar;20(2):89-93
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the cardia: classification as esophageal or gastric cancer?
  • INTRODUCTION: The cardia is the anatomical borderland between the esophagus and stomach.
  • Carcinomas of the cardia are regarded to share features of both, esophageal and gastric cancers.
  • CLASSIFICATION: In order to distinguish cardia carcinomas from other adenocarcinomas arising within the vicinity of the esophagogastric junction, a classification system has been introduced from a surgical viewpoint, and is now well established and increasingly used worldwide.
  • According to the topography of the main tumor mass, cardia carcinomas (AEG II) are distinguished from adenocarcinomas of the distal esophagus (AEG I) and subcardiac gastric cancers (AEG III).
  • The use of the classification for esophageal or for gastric cancers is recommended, irrespective of the elementary differences in the classification of lymphatic spread implemented herein.
  • The controversies concerning the classification of cardia carcinomas and the failure of the current esophageal and gastric cancer staging systems to reflect the peculiarities of this entity accurately, present a strong argument in favor of a new classification system.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms / classification. Stomach Neoplasms / classification

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1035-40 [11996237.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Chirurg. 1987 Jan;58(1):25-32 [3829805.001]
  • [Cites] Chirurg. 2003 Aug;74(8):703-8 [12928790.001]
  • [Cites] Surg Endosc. 2002 Apr;16(4):671-3 [11972212.001]
  • [Cites] Curr Oncol Rep. 2003 May;5(3):203-9 [12667417.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1076-7 [12190670.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jan;111(1):85-94; discussion 94-5 [8551792.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):402-9 [10716154.001]
  • [Cites] World J Surg. 2003 Mar;27(3):334-8 [12607062.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):387-98 [12057146.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] J Thorac Cardiovasc Surg. 1981 Aug;82(2):190-3 [7253683.001]
  • [Cites] Dis Esophagus. 2002;15(2):109-16 [12220416.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1052-7 [12917758.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):30-40 [9934728.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 15688098.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 22
  •  go-up   go-down


87. Wang Y, Guo W, He Y, Chen Z, Wen D, Zhang X, Wang N, Li Y, Ge H, Zhang J: Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control; 2007 Mar;18(2):143-52
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the association between the C to T transition in the methylenetetrahydro folate reductase gene (MTHFR C677T) and the C to T transition in the serine hydroxymethyltransferase ( 1 )gene (SHMT ( 1 ) C1420T) and the increased risk of carcinogenesis of esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA) in a population of high incident region of Northern China.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia. Esophageal Neoplasms / genetics. Glycine Hydroxymethyltransferase / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasms, Squamous Cell / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206530.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.2.1 / Glycine Hydroxymethyltransferase
  •  go-up   go-down


88. Souza RF, Spechler SJ: Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin; 2005 Nov-Dec;55(6):334-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach.
  • For decades, the incidence rates for squamous cell carcinoma of the esophagus and adenocarcinoma of the distal stomach have been declining while the rates for adenocarcinomas of the esophagus and gastric cardia have increased profoundly.
  • Recent studies have shown that the gastroesophageal junction (GEJ) is regularly exposed to concentrated gastric acid and to a variety of nitrosating species, noxious agents that may contribute to carcinogenesis in this region.
  • For adenocarcinomas that straddle the GEJ, it can be difficult to determine whether the tumor originated in the esophagus or in the gastric cardia.
  • Current concepts in the prevention of cancers of the distal esophagus and proximal stomach have emerged from advances in our understanding of the specific molecular events that occur during the evolution of these tumors.
  • The similarities and differences in risk factors, molecular pathogenesis, and in preventive strategies for adenocarcinomas of the esophagus and gastric cardia are highlighted.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282279.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 182
  •  go-up   go-down


89. Gretschel S, Schlag PM: Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach. Recent Results Cancer Res; 2010;182:107-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach.
  • The resection of the adenocarcinoma of the esophagogastric junction should be considered to the extent of the lymphatic drainage.
  • As an adenocarcinoma of the esophagogastric junction is located along the borderline between two visceral cavities (mediastinal/abdominal), it can, in principle, metastasize in both cavities.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676875.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


90. Abnet CC, Kamangar F, Dawsey SM, Stolzenberg-Solomon RZ, Albanes D, Pietinen P, Virtamo J, Taylor PR: Tooth loss is associated with increased risk of gastric non-cardia adenocarcinoma in a cohort of Finnish smokers. Scand J Gastroenterol; 2005 Jun;40(6):681-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tooth loss is associated with increased risk of gastric non-cardia adenocarcinoma in a cohort of Finnish smokers.
  • MATERIAL AND METHODS: A prospective cohort study with 29,124 subjects included 49 esophageal squamous cell carcinomas, 66 esophageal/gastric cardia adenocarcinomas, and 179 gastric non-cardia adenocarcinomas occurring between 1985 and 1999.
  • Odds ratios and 95% CIs were calculated with and without adjustment for H. pylori seropositivity in a nested case-control group to determine whether H. pylori confounded the association between tooth loss and gastric cancer.
  • RESULTS: Tooth loss significantly increased the hazard ratio for gastric non-cardia cancer, the HR (95% CI) for edentulous subjects versus those with < 10 teeth lost was 1.65 (1.09, 2.49, respectively).
  • No statistically significant associations were found between tooth loss and esophageal squamous cell carcinoma or esophageal/gastric cardia adenocarcinoma.
  • CONCLUSIONS: Tooth loss was associated with increased risk of gastric non-cardia cancer, but not esophageal squamous cell carcinoma or esophageal/gastric cardia adenocarcinoma in this Finnish cohort.
  • [MeSH-major] Adenocarcinoma / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Smoking / epidemiology. Stomach Neoplasms / epidemiology. Tooth Loss / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036528.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01CN45035; United States / NCI NIH HHS / CN / N01CN45165
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Norway
  •  go-up   go-down


91. Hanyu T, Kanda T, Matsuki A, Hasegawa G, Yajima K, Tsuchida M, Kosugi S, Naito M, Hatakeyama K: Endobronchial metastasis from adenocarcinoma of gastric cardia 7 years after potentially curable resection. World J Gastrointest Surg; 2010 Aug 27;2(8):270-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastasis from adenocarcinoma of gastric cardia 7 years after potentially curable resection.
  • Endobronchial metastasis (EBM) is a rare form of metastasis from extrapulmonary malignant tumors, although there are few reports of EBM from gastric cancer specifically.
  • We report the case of a 51-year-old woman who had undergone gastrectomy for advanced gastric cancer seven years previously but was diagnosed with a solitary lung tumor by follow-up computed tomography.
  • On diagnosis of primary lung cancer, she underwent pulmonary lobectomy, but immunohistochemical examination confirmed the resected tumor to be an EBM from the gastric cancer.
  • Six months later, she was diagnosed with peritoneal metastases and underwent chemotherapy with gastric cancer regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160887.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999249
  • [Keywords] NOTNLM ; Endobronchial metastasis / Gastric cancer / Immunohistochemistry
  •  go-up   go-down


92. Mattioli S, Ruffato A, Di Simone MP, Corti B, D'Errico A, Lugaresi ML, Mattioli B, D'Ovidio F: Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors. Ann Thorac Surg; 2007 May;83(5):1814-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors.
  • BACKGROUND: The morphologic and immunohistochemical profiles of gastric mucosa and of the tumor were assessed in Siewert type I, type II, and gastric antrum adenocarcinomas.
  • METHODS: Sixty-two patients, prospectively operated upon, were included in the study: 37 type II, 15 type I, and 10 antrum adenocarcinoma.
  • Samples of the tumor, the surrounding area, and the gastric corpus and antrum were analyzed histologically, and immunostained for cytokeratins (CK)7/20 (staining positive for cells labeled > or = 50%).
  • (1) 13 of 37 (35%) had intestinal metaplasia (IM) in the stomach;.
  • (5) 100% showed the same CK immunoprofile, both in IM and adenocarcinoma (measure of agreement k = 1, p = 0.000).
  • (2) 100% gastric samples devoid of both IM and HP infection.
  • One hundred percent of antrum adenocarcinomas showed a no Barrett's type CK profile, both in the tumor and in the IM of the entire stomach.
  • CONCLUSIONS: Data suggest that type II adenocarcinoma cannot be always considered a gastroesophageal reflux disease-related tumor; other pathogenetic pathways should be taken into consideration.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barrett Esophagus / pathology. Cardia / pathology. Esophagogastric Junction / pathology. Female. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Pyloric Antrum / pathology


93. Azarhoush R, Keshtkar AA, Amiriani T, Kazemi-Nejad V: Relationship between p53 expression and gastric cancers in cardia and antrum. Arch Iran Med; 2008 Sep;11(5):502-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between p53 expression and gastric cancers in cardia and antrum.
  • BACKGROUND: The mutations in p53 gene and accumulation of p53 protein are the most common genetic events in gastric carcinomas.
  • The present study was conducted to compare the frequency of p53 gene overexpression in a consecutive series of adenocarcinomas arising from the cardia and the antrum.
  • METHODS: Retrospective analysis was performed on 111 patients with gastric cancer who had undergone upper gastrointestinal endoscopies in 5th Azar Medical Center (northeastern, Iran), during 1998-2005.
  • The series comprised of 25 patients with cardia adenocarcinoma and 86 patients with antral adenocarcinoma. p53 alteration (nuclear p53 overexpression) was detected by immunohistochemistry.
  • RESULTS: Nuclear p53 overexpression was found in 14 (56%) out of the 25 and 27 (31.3%) out of the 86 patients with cardia and antral adenocarcinomas, respectively. p53 gene overexpression was significantly more frequent in adenocarcinomas of the cardia than the antrum.
  • CONCLUSION: This study shows that p53 alterations correlate well with gastric location, and they are more frequent in adenocarcinoma of the cardia than the antrum.
  • This result reinforce the hypothesis that the cancers of the lower esophagus and upper stomach have distinct epidemiologic, pathogenesis, and molecular characteristics from that observed in cancers of the lower part of the stomach.
  • [MeSH-major] Adenocarcinoma / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia. Female. Gene Expression. Humans. Male. Middle Aged. Pyloric Antrum

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759514.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


94. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH: Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control; 2009 Apr;20(3):361-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.
  • A number of risk factors for esophageal and gastric cancers have emerged, yet little is known whether risk factors map to molecular tumor markers such as overexpression of the tumor suppressor TP53.
  • Using a US multicenter, population-based case-control study (170 cases of esophageal adenocarcinomas, 147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, and 112 esophageal squamous cell carcinomas), we examined whether the risk associated with cigarette smoking, body mass index (BMI), gastroesophageal reflux disease (GERD), and non-steroidal anti-inflammatory drug (NSAID) use varied by P53 overexpression.
  • The proportion of cases overexpressing P53 by tumor subtype was 72% for esophageal adenocarcinoma, 69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67% for esophageal squamous cell carcinoma.
  • For non-cardia gastric cancer however, an association with cigarette smoking was suggested for tumors that do not overexpress P53, whereas larger BMI was related to adenocarcinomas that overexpress P53 versus no overexpression.
  • Overall, this study did not find a clear relationship between P53 protein overexpression and the known risk factors for subtypes of esophageal and gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Vojnosanit Pregl. 2005 Dec;62(12):879-85 [16375215.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2914-8 [8187077.001]
  • [Cites] Carcinogenesis. 1995 May;16(5):993-1002 [7767998.001]
  • [Cites] Pathol Res Pract. 1994 Dec;190(12):1141-8 [7540752.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):425-32 [9028350.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Mod Pathol. 2001 May;14(5):397-403 [11353048.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):233-40 [11902578.001]
  • [Cites] Oncology. 2002;62(2):175-9 [11914604.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1729-35 [14583777.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):779-82 [9332759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1065-9 [9419404.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Cancer. 1998;77(2):277-86 [9460999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):591-7 [10223186.001]
  • [Cites] J Pathol. 1999 Jan;187(1):8-18 [10341702.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):63-8 [15621992.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):225-30 [15765441.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • (PMID = 18989634.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] None / None / / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; None / None / / U01 CA057983-03; United States / Intramural NIH HHS / / Z01 CP010136-12; United States / NCI NIH HHS / CA / U01 CA057923; United States / NCI NIH HHS / CA / U01 CA 57923; United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NCI NIH HHS / CA / U01 CA 57983; United States / NCI NIH HHS / CA / U01 CA 57049; None / None / / U01 CA057949-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS100106; NLM/ PMC2726999
  •  go-up   go-down


95. Lindblad M, Ye W, Lindgren A, Lagergren J: Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg; 2006 Apr;243(4):479-85
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates.
  • OBJECTIVE: To evaluate the diagnostic accuracy of esophageal and cardia adenocarcinoma in the Swedish Cancer Register.
  • SUMMARY BACKGROUND DATA: Based on cancer registers, a rising incidence of esophageal and cardia adenocarcinoma has been reported in several populations, but possible influence of differences in tumor classification has not been evaluated.
  • METHODS: In a nationwide study in 1995 through 1997, all Swedish patients, born in Sweden and younger than 80 years with esophageal or cardia adenocarcinoma and half of all patients with esophageal squamous cell carcinoma, were prospectively, uniformly, and thoroughly classified.
  • RESULTS: The overall completeness of the Cancer Register was high (98.3%), whereas the site-specific completeness of the Register was 63% for esophageal adenocarcinoma, 74% for cardia adenocarcinoma, and 91% for esophageal squamous cell carcinoma.
  • The incidence of esophageal adenocarcinomas was 16% higher in the study classification compared with that of the Register during the study period, whereas the incidence of cardia adenocarcinoma was 2% lower in the study classification.
  • CONCLUSIONS: There is a diagnostic mismatch between esophageal and cardia adenocarcinoma in the clinical setting and, therefore, also in Cancer Registers.
  • The increasing incidence rate of esophageal adenocarcinoma in Sweden is unlikely to be explained by such differences in tumor classification, however.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / classification. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg. 2001 Oct;167(10):748-57 [11775726.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Chirurg. 1987 Jan;58(1):25-32 [3829805.001]
  • [Cites] Ugeskr Laeger. 1987 Jul 6;149(28):1904-9 [3433407.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):374-7 [8472157.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1082-6 [11099062.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):786-90 [10328109.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):834-42 [10360663.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • (PMID = 16552198.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448962
  •  go-up   go-down


96. Wang LD, Qin YR, Fan ZM, Kwong D, Guan XY, Tsao GS, Sham J, Li JL, Feng XS: Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China. Dis Esophagus; 2006;19(6):459-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China.
  • In China, gastric cardia adenocarcinoma (GCA) shares very similar geographic distribution with SCC, suggesting the possibility of similar risk factors involved in SCC and GCA carcinogenesis in these areas.
  • However, the underlying genetic alterations for esophageal and gastric cardia carcinogenesis, especially for the molecular difference between SCC and GCA, are largely unknown.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069589.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Carman S, Kamangar F, Freedman ND, Wright ME, Dawsey SM, Dixon LB, Subar A, Schatzkin A, Abnet CC: Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study. Int J Cancer; 2009 Jul 1;125(1):165-70
Hazardous Substances Data Bank. VITAMIN E .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study.
  • We investigated the association of dietary alpha-tocopherol, gamma-tocopherol and supplemental vitamin E intake with the risk of esophageal squamous cell carcinoma (n = 158), esophageal adenocarcinoma (n = 382), gastric cardia adenocarcinoma (n = 320) and gastric noncardia adenocarcinoma (GNCA; n = 327) in the NIH-AARP Diet and Health Study, a cohort of approximately 500,000 people.
  • For dietary alpha-tocopherol, we found some evidence of association with decreased esophageal squamous cell carcinoma and increased esophageal adenocarcinoma risk in the continuous analyses, with adjusted hazard ratios and 95% confidence intervals of 0.90 (0.81-0.99) and 1.05 (1.00-1.11), respectively, per 1.17 mg (half the interquartile range) increased intake.
  • There was no association between dietary alpha-tocopherol and gastric cardia adenocarcinoma or GNCA.
  • [MeSH-major] Diet. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology. Tocopherols / administration & dosage
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma, Squamous Cell / epidemiology. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. National Institutes of Health (U.S.). Prospective Studies. Risk Factors. Surveys and Questionnaires. United States / epidemiology. alpha-Tocopherol / administration & dosage. gamma-Tocopherol / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):133-40 [10861464.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):626-31 [10797282.001]
  • [Cites] Am J Epidemiol. 2000 Aug 1;152(3):279-86 [10933275.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):163-72 [11246845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):35-41 [11815399.001]
  • [Cites] Lancet. 2002 Jul 6;360(9326):23-33 [12114037.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):617-23 [12296509.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] Nutr Cancer. 1987;9(2-3):81-92 [3562297.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):896-901 [2335393.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):638-44 [8194870.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):393-8 [7920206.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):7-12 [9533754.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):601-5 [10521793.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2087-92 [16172214.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):406-15 [16832408.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1128-35 [17548674.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2323-30; quiz 2331 [17581269.001]
  • [Cites] Cancer Causes Control. 2003 Aug;14(6):547-58 [12948286.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1414-6 [13130117.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):444-9 [15297937.001]
  • [Cites] Am J Epidemiol. 1985 Dec;122(6):947-59 [2998182.001]
  • [Cites] Public Health Nutr. 2008 Feb;11(2):183-95 [17610761.001]
  • [Cites] J Nutr. 2003 Mar;133 Suppl 3:933S-940S [12612179.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):575-80 [12384802.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):737-48 [10679641.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):750-4 [10925371.001]
  • (PMID = 19326432.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010196-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS109107; NLM/ PMC2686122
  •  go-up   go-down


98. Kutup A, Yekebas EF, Izbicki JR: Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:115-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Esophageal and gastric cancers are aggressive neoplasms with a poor prognosis.
  • The potential role and -benefit of an antibody-based treatment as a therapeutic target would be of particular interest in tumors with a notoriously poor prognosis such as esophageal cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676876.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


99. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S: The prognosis of gastric cardia cancer after R0 resection. Am J Surg; 2010 Jun;199(6):725-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of gastric cardia cancer after R0 resection.
  • BACKGROUND: The aim of this study was to evaluate the prognosis of gastric cardia cancers in comparison with other gastric cancers.
  • METHODS: The medical records of 251 patients with gastric cardia cancers and 6568 patients with other gastric cancers who underwent R0 resection were reviewed.
  • RESULTS: Gastric cardia cancer was associated with more advanced staging and less favorable clinicopathologic features at diagnosis compared with other gastric cancers.
  • The overall 5-year survival rates were 79.7% and 84.6% in patients with cardia cancer and other cancers, respectively.
  • CONCLUSIONS: Although patients with gastric cardia cancers are diagnosed at an advanced stage, the long-term survival rates are similar to those with other gastric cancers.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia / surgery. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19837398.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Jansson C, Jeding K, Lagergren J: Job strain and risk of esophageal and cardia cancers. Cancer Epidemiol; 2009 Dec;33(6):473-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Job strain and risk of esophageal and cardia cancers.
  • BACKGROUND: Few studies have investigated work-related stress in relation to esophageal or cardia cancers.
  • METHODS: Our nationwide Swedish population-based case-control study included 189 and 262 esophageal and cardia adenocarcinoma cases respectively, 167 esophageal squamous-cell carcinoma cases and 820 controls.
  • RESULTS: Job strain was positively associated with risk of esophageal adenocarcinoma (OR 3.2, 95% CI 1.0-9.8) and squamous-cell carcinoma (OR 4.0, 95% CI 1.6-10.5), but not with cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology. Stress, Psychological. Workload / psychology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926547.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement